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I. Abstract 
Atrial fibrillation (AF) is the most common arrhythmia and is closely associated with 
chronic kidney disease. The mainstay pharmacological agent to prevent AF-related 
stroke and thromboembolism is the use of oral anticoagulants, but may result in an 
increased risk of haemorrhage. Therefore, this MD research thesis is a 
comprehensive study of the changes in thrombogenesis and fibrin clot structure 
related to AF and CKD, as well as the potential impact of exposure to different 
classes of oral anticoagulant.   
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1.1 Atrial Fibrillation and Chronic Kidney Disease – pathophysiology 
and clinical implications 
Introduction 
Chronic Kidney Disease (CKD) is defined by the Kidney Disease Improving Global 
Outcomes (KDIGO) as a reduction in renal function; with a reduction in glomerular 
filtration rate(GFR) <60ml/min per 1.73m2 for 3 months or longer, or with the 
presence of albuminuria (1, 2). CKD has potential for gradual progression to End-
stage Renal Disease (ESRD) which requires dialysis to correct accompanying fluid and 
electrolyte imbalance. The increasing incidence and prevalence of CKD is also 
associated with a parallel rise in incident atrial fibrillation (AF) occurrence (3-6). The 
main reason for this epidemiological coupling is most likely the improving longevity 
achieved in the western countries, resulting in a rapidly growing older population, 
with a contemporary increase in the collective risk factors, shared by both 
conditions, such as diabetes mellitus and hypertension.   
Unsurprisingly, it has been demonstrated that CKD and AF are not independent, as 
several studies and national registries have highlighted the increased incidence of AF 
among those with worsening renal function (7-14).  For example, recent data show 
the incidence of AF development can be as high as 12.1 per 1000 patient-years in 
ESRD as compared to 5.0 per 1000 patient-years in controls (15). Likewise, a new 
diagnosis of AF not only heralds the progression of CKD, but seems also to hasten the 
development of ESRD (16-18). AF also leads to progression of CKD, even among 
those with relatively “normal renal function” with no detectable proteinuria on 
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dipstick at baseline (19). Thus, a bidirectional relationship exists between these two 
conditions. 
AF per se can result in increased risk of ischaemic stroke and systemic 
thromboembolism by five-fold, and is implicated in 15-20% of all ischaemic strokes 
(20). However, the concurrent presence of both AF and CKD further exacerbates the 
stroke and mortality risk, with upwards of 66% increase in relative risk of death (21-
24).    
Hence, the intersection of both conditions results in an increase in the propensity for 
thromboembolism-related adverse events (including stroke, systemic 
thromboembolism, myocardial infarction and death) but in addition, a paradoxical 
increased risk of haemorrhagic sequelae.  
Stroke and thromboembolic risk can be assessed using the CHA2DS2-VASc Score 
while bleeding risk can be assessed by the HAS-BLED Score, to allow for careful risk 
stratification of the patient requiring thromboprophylaxis (25, 26). Oral 
anticoagulants (whether Vitamin K antagonists (VKA) and Non-VKA oral 
anticoagulants (NOACs)) have been demonstrated to be effective in mild-moderate 
renal dysfunction, in both clinical trials and observational studies (27, 28).   
Patients with severe renal impairment were excluded from the Phase 3 randomised 
trials of NOACs, so limited trial data are available.   
This chapter will initially discuss the pathophysiological and clinical basis behind the 
increased risk of thromboembolism and haemorrhage amongst AF patients with 
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CKD.  Second, we review the data on the use of oral anticoagulants for stroke 
prevention in AF across the spectrum of renal dysfunction. 
Search Strategy 
A comprehensive literature search by using electronic bibliographic databases (i.e., 
Pubmed, Medline, Embase, DARE, Cochrane database), scanning reference lists from 
included articles, and hand searching abstracts from national and international 
cardiovascular meetings. Search terms used include “atrial fibrillation”, “chronic 
kidney disease”, “renal failure”, “anti-thrombotic treatment”. Bibliographies of all 
selected articles and review articles were reviewed for other relevant articles. 
Finally, the supplements of major journals were hand searched to identify relevant 
abstracts that had not been published as peer-reviewed articles.  
 
Pathophysiology and epidemiology of thromboembolism in CKD: A brief overview 
Pathophysiological insights 
AF confers a prothrombotic or hypercoagulable state through numerous 
pathophysiological pathways fulfilling ‘Virchow’s triad for thrombogenesis’, as 
evidenced by abnormalities in vessel wall, abnormalities in flow and abnormalities in 
blood constituents (29). The propensity for thrombus formation is further enhanced 
by CKD [Table 1.1.1] due to additional changes to the flow within the left atrium and 
left atrial appendage, damage to vessel wall and subsequent endothelial 
dysfunction, or upward regulation of platelet and coagulation factors [Figure 1.1.1].   
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Firstly, in relation to changes in blood flow, worsening GFR in AF is associated with 
reduced left atrial appendage emptying velocity and formation of dense 
spontaneous echocardiographic contrast, signifying significantly increased 
thrombogenic risk (30, 31).  
Secondly, CKD-related endothelial dysfunction and damage to the vessel wall may 
manifest directly as reduction in endothelial dilatation or increased pulse-wave 
velocity (32-36), or indirectly by elevated levels of endothelin and vWF (33, 37). 
Endothelial dysfunction can also be reflected by the increased intima media 
thickening (38), which subsequently has been shown to predict upwards of 10-fold 
(Odds-ratio 10.20 (95% CI, 3.67 to 28.3)) increased cardiovascular mortality in ESRD 
(39, 40). 
Thirdly, increased thrombogenesis in CKD is also related to increased platelet and 
coagulation abnormalities in several pathways: increased pro-coagulant and 
inflammatory complexes (41-45), up-regulation of tissue factor pathway and its 
interaction with platelets (46, 47), reduction of antithrombin III and PAI-1 levels (47, 
48), reduced vWF degradation (49) and increased platelet aggregability (50).  
Furthermore, CKD per se is associated with various other factors contributing to an 
increased thromboembolic risk: for example, activation of the renin-angiotensin-
aldosterone-system (RAAS) (51) and chronic inflammation (43), aortic or vascular 
calcification plus dysfunction of calcium-phosphate-mineral metabolism related to 
renal dysfunction (52-54).  Given the aforementioned pathophysiological pathways, 
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it is perhaps unsurprising for CKD to result in an elevated risk of ischaemic stroke and 
systemic thromboembolism.  
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Table 1.1.1: Pathophysiology of Thromboembolism in Chronic Kidney Disease 
 
Study (Year) Study Type N Population Findings 
(a) Blood stasis in left atrium and atrial appendage 
Yagishita et al (2010) 
(30)  
Observational 321 Patients with persistent 
atrial fibrillation 
GFR an independent predictor of reduced left atrial 
appendage emptying velocity and presence of left atrium 
spontaneous echo contrast 
Providência et al 
(2013) (31) 
Observational 372 Patients with nonvalvular 
atrial fibrillation 
eGFR is positively associated with dense spontaneous 
echocardiographic contrast, and low flow velocities in the 
left atrial 
 
(b) Damage to vessel wall and endothelial damage/dysfunction 
Heintz et al (1994) 
(37) 
Comparative 40 CKD and healthy controls CKD patients have higher endogenous levels of ET-1, plasma 
cAMP, and enhanced ET-1 stimulated ADP-induced platelet 
aggregation than healthy control 
Blacher et al (1999) 
(32) 
Observational 241 ESRD patients Increased aortic PWV in ESRD predicts all-cause 
cardiovascular mortality. 
Bolton et al (2000) 
(33) 
Cross-
sectional 
67 23 HD patients, 16 NDD 
patients and 28 healthy 
control 
Reduced flow-mediated EDD in HD and NDD patients 
compared to control. Increased vWF and adhesion 
molecules in renal dysfunction. 
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Yildiz et al (2003) 
(34) 
Comparative 104 104 HD patients vs 49 
healthy controls 
Reduced flow-mediated EDD and EID in haemodialysis 
patients compared to control. 
Hrafnkelsdóttir et al 
(2004) (55) 
Comparative 18 Non-diabetic, non-smoking 
CKD patients and age-
matched control 
Maximal release of active tPA and capacity for active tPA 
release markedly impaired in CKD patients vs controls 
Wang et al (2005) 
(35) 
Observational 102 NDD CKD patients with 
various GFR 
Decreased GFR was independently associated with an 
increased PWV. 
Carrero et al (2012) 
(36) 
Observational 630 NDD CKD vs ESRD Prolactin levels increased along with reduced kidney 
function, related to FMD, PWD and increased risk of 
cardiovascular events and mortality. 
Recio-Mayoral et al 
(2011) (38) 
Comparative 141 76 CKD vs 65 age and 
gender matched control 
CKD patients had increased CRP levels, reduced FMD and 
increased IMT values compared to controls 
 
(c) Platelet and coagulation abnormalities 
Shlipak et al (2003) 
(41) 
Cross-
sectional 
5888 Population-based cohort of 
age >65 years old 
CRP, fibrinogen, IL-6, Factor VII, Factor VIII, plasmin-
antiplasmin complex, and D-Dimer levels significantly higher 
in CKD 
Pecoits-Filho et al 
(2003) (42) 
Observational 176 176 NDD patients Lower GFR associated with increased CRP, IL-6, hyaluronan 
and neopterin levels.  
Keller et al (2008) 
(43) 
Cross-
sectional 
6814 Population-based cohort 
45-84 
CRP, IL-6, TNF, TNF-αR1,  intercellular adhesion molecule-1, 
fibrinogen, and Factor VIII levels are significantly higher in 
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CKD 
Landray et al (2004) 
(44) 
Comparative 522 334 CKD patients, 92 CAD 
patients, 96 healthy control 
with no prior CV or renal 
disease 
CKD is associated with higher fibrinogen, plasma vWF, 
soluble P-selectin, but not CRP 
Tanaka et al (2009) 
(45) 
Observational 190 Patients not receiving oral 
anticoagulant stratified to 
CCr 
Decreased GFR predicts for elevation of TAT and D-Dimer in 
patients with AF  
Mercier et al (2001) 
(46) 
Cross-
sectional 
150 50 ESRD patients, 50 NDD 
CKD and 50 healthy controls 
Reduced renal function associated with enhance tissue 
factor coagulation to platelet, monocyte and endothelial 
injury. 
Costa et al (2008) 
(48) 
Observational 50 50 ESRD patients vs 25 
healthy controls 
Higher levels of CRP, s-IL2R, IL-6 and D-dimers, and 
significantly lower levels of PAI-1 in ESRD patients. The 
tPA/PAI-1 ratio was also significantly higher in ESRD 
patients. 
Adams et al (2008) 
(47) 
Comparative 102 66 CKD stage 4&5 vs 36 
healthy controls 
Up-regulation of the tissue factor pathway, increased 
prothrombin fragment 1+2 and reduction in antithrombin III 
in CKD compared to healthy controls 
 
Shen et al (2012) 
(49) 
Observational 104 104 NDD vs 32 healthy 
controls 
Increased vWF-antigen level and decreased ADAMTS13 
activity in CKD. 
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Yagmur et al (2015) 
(50) 
Comparative 84 30 HD patients, 34 renal 
transplant recipients, 20 
healthy controls 
Increased platelet hyperaggregability in CKD. 
 
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; ADP, adenosine 
diphosphate; AF, atrial fibrillation; CAD, coronary artery disease; cAMP, cyclic adenosine monophosphate; CCr, Creatinine clearance; CKD, 
chronic kidney disease; CV, cardiovascular; CRP, C-reactive protein; EDD, endothelium-dependent dilatation; eGFR, estimated glomerular 
filtration rate; EID, endothelium-independent dilatation; ESRD, End-stage renal disease; ET-1, Endothelin 1; FMD, flow-mediated dilation; GFR, 
glomerular filtration rate; HD, haemodialysis; IL-6, interleukin-6; intima-media thickness, IMT; MDRD, Modification of Diet in Renal Disease; 
NDD, non-dialysis dependent; PWV, pulse wave velocity; s-IL2R, serum interleukin-2 receptor ;TAT, thrombin-antithrombin complex; TNF-αR1, 
tumour necrosis factor-α soluble receptor 1; tPA, tissue plasminogen activator; vWF, von Willebrand factor. 
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*2. Endothelial 
dysfunction/damageAs evidenced by 
increased intima media thickening, 
increased pulse wave velocity and 
reduced endothelial dilatation, 
resulting in endothelial dysfunction. 
 
*1 
*1. Reduced left atrial appendage 
emptying velocity induces stasis 
As evidenced by increased 
spontaneous echocardiographic 
contrast. This reflects stasis of 
blood and spontaneous 
thrombus formation 
1 1 
1 1 
1 
*3. Increased coagulation and 
platelet abnormalities 
Figure 1.1.1: Pathophysiology of Thromboembolism in Chronic Kidney Disease and 
Atrial Fibrillation 
Thrombus Formation 
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Epidemiological insights 
The increase in stroke risk with progressive severe CKD amongst AF patients has 
been reported by several large observational studies, as shown in Table 1.1.2.   
The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study (56) found 
that the presence of proteinuria increased risk of thromboembolism in AF by 54%; 
and progressive worsening of GFR was also associated with increased risk of stroke, 
so much so that those with GFR <45 mL/min/1.73 m2 conferred an increased risk of 
39% as compared to those with GFR >60 mL/min/1.73 m2.  
In separate analyses from the Danish nationwide cohort, Olesen et al (57) and Bonde 
et al (58) reported that patients with concurrent AF and CKD experience significantly 
higher rates of stroke, thromboembolism, haemorrhage and death, as compared 
with those without renal disease. Those with ESRD requiring renal replacement 
therapy fared the worst as they are twice as likely to experience stroke and 
thromboembolism (58) compared to those without renal dysfunction, with an 
incidence rate up to 6.9 per 100 patient-years (59).  
Similar relationships between increased incidences of AF with progressive renal 
failure, with resultant increased in adverse events were exhibited amongst the 
Swedish national cohort study as well as some Asian countries (15, 60-62).  
Furthermore, amongst those with CKD (GFR <60ml/min per 1.73m2), the sequential 
deterioration of renal function over time has been shown to be equally pertinent, as 
an absolute reduction in eGFR ≥25 mL/min/1.73 m2 or a relative reduction of eGFR 
≥25% effectively more than doubles the risk of ischaemic stroke when compared to 
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those with relatively “stable” renal function over 6 months period (18). Even among 
AF patients treated with effective anticoagulation, every 30ml/min per 1.73m2 
reduction in eGFR confers an increased risk of thrombotic or vascular events (HR 
1.42; 95%CI 1.11 – 1.83) (63). 
More recent evidence also reveals that worsening renal clearance not only is an 
independent, reliable predictor of stroke mortality, but is also associated with a 
worse adverse clinical outcome after stroke (64, 65).   
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Table 1.1.2: Epidemiological insight into stroke risk in patients with atrial fibrillation and chronic kidney disease 
 
Stroke Risk in AF with CKD 
Study Study Type N Findings 
Go et al (2009) (56) Retrospective 10908 AF with CKD Comparing with GFR ≥ 60 mL/min/1.73 m2: 
eGFR 45-59mL/min, RR 1.16 (95% CI, 0.95 to 1.40)  
eGFR < 45mL/min, RR 1.39 (95% CI, 1.13 to 1.71  
(P = 0.0082 for trend). 
Friberg et al (2012) 
(66) 
Retrospective 182678 AF patients  
(out of which 8113 had CKD) 
CKD Stage 1 and below: Multivariate HR 1.11(95% CI 0.99-1.25) 
Olesen et al (2012) 
(57) 
Retrospective 132372 AF patients  
(out of which 3587 NDD CKD, 
901 ESRD) 
Comparing with GFR ≥ 90 mL/min/1.73 m2: 
NDD CKD, HR 1.49 (95% CI 1.38-1.59) 
ESRD, HR 1.83 (95% CI, 1.57 to 2.14) 
Guo et al (2013) 
(18) 
Prospective 617 AF patients Risk of stroke or death: HR 2.90 (95% CI 1.88-4.48) 
Risk of stroke in 6 months: 
Absolute decrease eGFR ≥ 25 mL/min/1.73 m2: HR 2.77 (95% CI 1.26-
23 
  
6.09) 
Relative decrease eGFR ≥ 25%: HR 2.57 (95% CI 1.14 – 5.80)   
Roldán V et al 
(2013) (63) 
Prospective 978 AF patients on VKA Every decrease eGFR 30 mL/min/1.73 m2 : HR 1.42 (95% CI 1.11 - 1.83) 
Bonde at al (2014) 
(58) 
Retrospective 154254 non-valvular AF 
patients (out of which 148598 
NRD, 4519 NDD, 1142 on RRT) 
Comparing with GFR ≥ 60 mL/min/1.73 m2: 
NDD CKD, HR 1.32 (95% CI 1.23–1.42) 
RRT, HR 2.01 (95% CI 1.74–2.33) 
Chao TF et al 
(2014) (59) 
Retrospective 10999 AF patients with ESRD 
in Taiwan 
11.7% of patients experienced ischaemic stroke. 
Absolute stroke and thromboembolism event rate: 6.9 per 100 
patient year 
Banerjee A et al 
(2014) (67) 
Prospective 8962 AF patients 
(out of which 2982 with CKD) 
Comparing with GFR ≥ 60 mL/min/1.73 m2: 
eGFR 30-59 mL/min HR 1.53 (95% CI 1.10-2.12) 
eGFR < 30 mL/min HR 1.78 (95% CI 0.99-3.19)  
 
 
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; HR, hazard ratio; NDD, non-dialysis 
dependent; NRD, no renal disease; pts, patients; RR, relative risk; RRT, renal replacement therapy
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The haemorrhagic tendency in CKD 
Though CKD does increase the risk of thromboembolism and ischaemic stroke in AF, 
paradoxically it is also associated with an important increased risk of haemorrhagic 
sequelae as explained below. 
Evidence from both the Rotterdam Study and the Japanese CIRCS Study show that 
the mere presence of reduced renal function (GFR <60 mL/min/1.73 m2) resulted in 
an increased risk of haemorrhagic stroke with hazard ratios over 4-fold in male and 
7-fold in female patients (68, 69), while patients undergoing chronic dialysis had a 
relative risk of intracerebral haemorrhage that can be over 10-fold higher (70). There 
is also mounting evidence that worsening renal function and associated vascular 
dysfunction may result in increased tendency for formation of MRI-defined cerebral 
micro-bleeds, which have the potential of contributing to subsequent intra-cerebral 
haemorrhage (71). 
In addition, gastrointestinal (GI) bleeding is also increased, either peptic ulcer or non-
peptic ulcer-related and non-variceal bleeds; overall, the recurrence, frequency and 
severity of such episodes are all closely linked to impairment of renal function (72-
74). Similar to intracranial haemorrhage, both forms of renal replacement therapy 
(peritoneal dialysis and haemodialysis) is associated with an increased risk of 
gastrointestinal haemorrhage, conferring a hazard ratio of 3.71 (95 % CI 2.00 - 6.87) 
and 11.96 (95% CI 7.04 - 20.31), respectively (75). 
The pathophysiological causes of the increased risk of haemorrhagic sequelae are 
clearly multifactorial. These can be a direct result of uremia-related platelet 
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dysfunction or impaired platelet adhesion and aggregation, impaired platelet 
glycoprotein IIb-IIIa receptor activation and subsequent binding to glycoprotein, 
altered von Willebrand factor and nitric oxide metabolism (76-78). 
Extrinsically, the propensity to bleed can be a result of concurrent use of anti-
platelets or non-steroidal anti-inflammatory drugs for other associated disaease 
processes. Moreover, patients with ESRD would be subjected to frequent invasive 
diagnostic and treatment strategies, such as central venous access and 
haemodialysis (plus subsequent frequent heparin exposure), that could increase 
their bleeding risk. 
 
Stroke and bleeding risk stratification in AF with CKD  
In the AF population, the risk of stroke is increased by 5-fold overall, according to the 
presence or absence of various stroke risk factors. The common risk factors have 
been used to formulate stroke risk stratification scheme, to help decision making on 
whether OAC should be recommended or not, for stroke prevention. 
However, all clinical risk scores have modest predictive value for identifying ‘high 
risk’ patients who sustain events. AF guidelines have adopted the use of the 
CHA2DS2-VASc score [Table 1.1.3] given that it can reliably identify truly “low risk” 
patients (i.e. CHA2DS2-VASc score 0 in males, 1 in females), who do not need 
antithrombotic therapy (79, 80).  Subsequent to this step, effective stroke 
prevention can be offered to those AF patients with ≥1 stroke risk factor.   Effective 
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stroke prevention means OAC, whether as well-controlled VKA therapy or one of the 
NOACs. 
Despite being a contributor to an increased thromboembolic risk, moderate-severe 
renal impairment is not included in the CHA2DS2-VASc score, attempts to incorporate 
renal impairment into stroke risk stratification scheme did not suggest an 
independent additive predictive value for renal impairment over the CHA2DS2-VASc 
score components, probably due to the fact that CKD is strongly associated with the 
single risk factor components of the CHA2DS2-VASc score (i.e. heart failure, 
hypertension, diabetes, etc).  
One study advocating the addition of renal impairment for stroke risk stratification 
proposed the R2CHADS2 score (with the additional “R” for impaired renal function, 
and given 2 points).  In its initial derivation study, the R2CHADS2 score also modestly 
improved c-index (prediction value) of the CHADS2 and CHA2DS2-VASc scores (81-83). 
Nonetheless the aforementioned studies were either derived from an anticoagulated 
clinical trial population with exclusion of those with severe CKD (ROCKET-AF trial) 
(81), inclusion of a small sample size of ESRD cohort (82) or from a highly selected 
cohort undergoing invasive catheter ablation of AF (83).  However, the positive 
results of R2CHADS2 score were not replicated in other similar studies (84, 85).  Also, 
in other “real-world” non-anticoagulated AF cohorts, renal dysfunction did not 
independently improve predictive value of CHADS2 and CHA2DS2-VASc score (86, 87).   
Regarding haemorrhagic risk stratification in AF, guidelines currently recommend the 
use of the HAS-BLED score for assessing bleeding risk [Table 1.1.4]. Nevertheless, a 
high HAS-BLED score should not lead to withholding of effective oral anticoagulation 
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therapy. Instead, a high HAS-BLED score amongst those with CKD should ‘flag up’ the 
patients potentially at risk of bleeding for careful review or follow-up and for 
correction of modifiable risk factors such as uncontrolled hypertension (the H of the 
HAS-BLED), labile INRs, alcohol excess or concomitant use of NSAIDs and aspirin.   
For those patients who did experience previous gastrointestinal haemorrhagic 
sequelae, the resumption of anticoagulant treatment was actually associated with a 
significant reduction of mortality and thromboembolic events (88, 89). Similar 
findings have also been seen in ESRD cohort upon restarting warfarin amongst 
patients with an increased risk of recurrence of gastrointestinal bleed (90). 
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Table 1.1.3: The CHA2DS2-VASc score 
Congestive Heart Failure 1 
Hypertension 1 
Age ≥ 75 years 2 
Diabetes Mellitus 1 
History of Stroke/TIA/thromboembolism 2 
Vascular disease (previous myocardial infarction, peripheral 
vascular disease or aortic plaque) 
1 
Age (64-74 years) 1 
Sex category (female) 1 
Maximum score 9 
 
Table 1.1.4: The HAS-BLED Score 
Hypertension 1 
Abnormal renal and liver function (one point each) 1 
Stroke 2 
Bleeding history or propensity 1 
Labile INR 2 
Elderly (age > 65 or frail condition) 1 
Drugs or alcohol concomitant use 
(one point each) 
1 
Maximum score 9 
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Oral Anticoagulation in CKD:  using Vitamin K antagonists (VKA) 
Though oral anticoagulant is the mainstay of treatment in the prevention of 
ischaemic stroke and thromboembolic-related adverse outcomes in patients with AF 
population, less evidence exists for those with significant renal impairment, given 
that such patients were excluded from randomised trials. Hence, the prescription of 
classical oral anticoagulants (essentially VKAs e.g. warfarin) amongst those with 
significant renal impairment varies from as low as 2% in Germany to as high as 37% 
in Canada58. This heterogeneity in clinical practice reflects the uncertainty about the 
risks and benefits of anticoagulation use within this patient group. 
For AF patients with concomitant ESRD, requiring renal replacement therapy, 
conflicting findings exist from observational studies relating to the safety associated 
with use of VKA [Table 1.1.5].  
Of the 17 studies reviewed, only Abbott et al (91) showed a clear mortality benefit, 
while Olesen et al (92),  Bonde et al (58), Genovesi et al (93), Chan et al (94) and 
Findlay et al (95) demonstrated a reduction in event rate for stroke or 
thromboembolism. Other studies involving ESRD and VKA thromboprophylaxis have 
demonstrated either equivocal results (96-98) or even suggested that VKA can 
potentially cause harm in CKD patients with ESRD (96, 99-106).  
One large observational study (100) and several multinational cohort studies (101, 
104) have demonstrated that AF patients who are on haemodialysis and taking 
warfarin experienced more than two-fold increase in the risk of ischaemic stroke as 
compared to non-VKA users. Elderly patients (aged >75 years) appeared to be 
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particularly at risk as compared to those below 65 years (101). At the same time, 
those exposed to VKA whilst on haemodialysis may also face a higher risk of 
haemorrhagic stroke rather than thromboembolic event (103).  
Possible explanations for the lack of efficacy of VKA in protection against stroke and 
thromboembolism, and potentially contributing to the increase in stroke risk may be 
due to the low time in therapeutic range for patients receiving renal replacement 
therapy. Indeed, the Swedish AF cohort study suggests that the improved quality of 
anticoagulation control, as reflected by high time in therapeutic range (TTR), is 
associated with lower risk of thromboembolism and haemorrhage (107). 
Another possible explanation related to the lack of efficacy in reducing ischaemic 
stroke and haemorrhagic risk may potentially be dependent on the modality of renal 
replacement therapy used. A recent Hong Kong cohort suggested that patients 
receiving peritoneal dialysis have similar thrombotic risk as non-CKD counterparts 
while warfarin use in this particular patient group not only provided protection 
against ischaemic stroke, but does not appear to increase the risk of intracranial 
haemorrhage (94). 
Indeed, amongst non-dialysis dependent CKD patient with AF, there appears to be 
more robust data favouring the use of dose-adjusted VKA in AF [Table 1.1.6].  In all 5 
studies and 1 meta-analysis reviewed, dose-adjusted warfarin provided better 
protection against ischaemic stroke and systemic embolism, than no VKA- (57, 58, 
105, 108-110). The efficacy of warfarin in reducing thromboembolism has to be 
balanced against a small but significant increase in haemorrhage tendency (19% – 
36%), with even higher event rate if there is concurrent antiplatelet use (57, 105).     
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Therefore, though VKA can be beneficial in non-dialysis dependent patients with AF, 
the propensity for harm due to VKA in ESRD is yet to be fully defined, especially in a 
patient on haemodialysis. Thus the use of VKA for thromboprophylaxis against stroke 
and systemic thromboembolism in CKD patients requiring renal replacement therapy 
requires a careful evaluation of stroke and bleeding risks and the correction of 
reversible bleeding risk factors.   
What are the pathophysiological mechanisms?   
Murine and human studies have demonstrated that VKA contributes to vascular 
calcification through inactivation of matrix Gla protein (MGP) (111, 112). As MGP is a 
potent inhibitor of vascular calcification, the use of VKA will inhibit the final vitamin K 
dependent pathway, thus preventing phosphorylation and carboxylation of MGP into 
its active form (113, 114).  
The increased vascular calcification, either as a direct result of development of ESRD 
or due to concurrent VKA usage may potentially increase the likelihood of 
development of non-cardioembolic stroke, which will not be remedied by VKA use. 
Moreover, VKA administration has been implicated in development of calciphylaxis, 
a painful and lethal complication among patients with ESRD as cutaneous arteries 
and arterioles undergo calcification and occlusion (115, 116). The pathophysiology 
resulting in calciphylaxis remains poorly understood. 
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Table 1.1.5: Vitamin K antagonist use and stroke rates in end-stage renal disease 
VKA use in AF with ESRD 
Study Study Type Number  
(% with AF) 
Findings 
Wiesholzer et al 
(2001) (99) 
Retrospective 
observational 
430 (14.3%) Stroke rate per 100 patient year:  
AF with VKA: 4.46, 
AF without VKA: 1.0 
Abbott et al (2003) 
(91) 
Retrospective 
observational 
3374 (1.25%) 3-year survival rate:  
AF with VKA: 70% 
AF without VKA: 55% 
Chan et al (2009) 
(100) 
Retrospective 
observational 
48825 (3.42%) 90-day HR  – 
AF with VKA a:  1.93 (95% CI 1.29 – 2.90) 
Wizemann et al 
(2010) (101) 
Observational 
(DOPPS) 
17513 (12.5%) Stroke rate in >75 years old: 
Warfarin user: 2.17 (95% CI 1.04 – 4.53) 
Phelan et al (2011) 
(102) 
Retrospective 845 requiring dialysis (141 on 
warfarin) 
Stroke rate per 100 patient year: 
VKA user: 1.7 versus  Non-VKA user: 0.7  (p = 0.636) 
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Major haemorrhage rate per 100 patient year:  
VKA user: 10.8 versus Non-VKA user: 8.0 (p = 0.593) 
Winkelmayer et al 
(2011) (103) 
Retrospective 
observational 
2313 ESRD patients with new AF HR for ischaemic stroke: VKA user 0.92 (95% CI 0.61 – 1.37) 
 
HR for haemorrhagic stroke: VKA user 2.38 (95% CI 1.15 – 4.96)  
Olesen et al (2012) 
(57) 
Subgroup analysis 901 patients with AF requiring 
dialysis 
HR comparing with no antithrombotic, dialysis dependent pts: 
VKA: 0.44 (95% CI 0.69 – 1.01) 
Knoll et al (2012) 
(96) 
Prospective 235 patients on dialysis (19.6% on 
VKA) 
No stroke or bleed experienced. 
 
HR for mortality in VKA user: 0.80 (95% CI 0.28 - 2.29) 
 
Sood et al (2013) 
(104) 
Observational 
(DOPPS) 
41844 (9.71%) Stroke rate per 100 patient year:  
VKA b: 3.3 
No VKA or antiplatelet: 2.1 
Bonde at al (2014) 
(58) 
Retrospective 154254 non-valvular AF patients 
(out of which 1142 on RRT and 260 
Stroke and thromboembolic risk in non-VKA users: 
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receiving VKA) HR c: 1.82 (95% CI 1.58 - 2.12) 
Shah et al  
(2014) (105) 
Retrospective 1626 patients with AF on RRT (out 
of which 756 VKA users) 
HR for ischemic stroke comparing VKA vs non-VKA users: 1.14 
(95% CI 0.78 – 1.67)  
 
HR for bleeding: 1.44 (95% CI 1.13 - 1.85) 
Chen et al 
(2014) (98) 
Retrospective 500 with AF and ESRD (out of 
which 250 receiving VKA) 
Comparing with group of control (no VKA or antiplatelet): 
HR for ischemic stroke: 1.017 (95% CI 0.673–1.537)  
 
Wakasugi et al 
(2014) (106) 
Prospective 60 Japanese patients with AF 
requiring dialysis (out of which 28 
VKA users) 
Comparing VKA vs non-VKA users 
HR for ischemic stroke: 3.36 (95% CI 0.67–16.66) 
Chan et al (2015) 
(94) 
Retrospective 271 patients with AF on peritoneal 
dialysis (70 on VKA) 
Comparing VKA vs aspirin user: 
HR for ischaemic stroke: 0.16 (95% CI 0.04 – 0.66) 
 
Comparing VKS vs non-user of antithrombotic agents: 
HR for ischaemic stroke: 0.19 (95% CI 0.06 – 0.65) 
Findlay et al (2015) 
(95) 
Retrospective 1382 patients with ESRD out of 
which 293 with AF (118 on VKA, 
Stroke rate:  
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while 175 without VKA)  AF with VKA: 11.4% 
AF without VKA: 14.4% 
Genovesi et al 
(2015) (93) 
Prospective 290 patients with AF requiring 
dialysis (out of which 134 on VKA 
at recruitment) 
Comparing VKA vs non-VKA users: 
HR for stroke/thromboembolic events: 0.12 (95% CI 0.00-3.59) 
 
Shen et al (2015) 
(97) 
Retrospective 12284 pts on RRT (1383 started on 
VKA) 
Comparing VKA vs non-VKA users: 
 
HR for ischemic stroke: 0.68 (95% CI 0.47 - 0.99) 
HR for mortality: 0.84 (95% CI 0.73 - 0.97) 
Abbreviations: AF, atrial fibrillation; CI, confidence interval; DOPPS, Dialysis Outcomes and Practice Pattern Study; ESRD, end-stage renal 
disease; HR, hazard ratio; RRT, renal replacement therapy; VKA, Vitamin K antagonist 
 
 
a AF with VKA covariate adjusted model: adjusted for CHADS2 score, gender, race, Charlson comorbidity index, entry date, body mass index, 
facility standardised mortality ratio, cardiovascular drugs, dialysis adequacy, baseline laboratory values, heparin dosage and heparin regimes.  
b VKA user includes patients with atrial fibrillation, thromboembolic disease or central vascular catheter.  
c Adjusted for Aspirin treatment and all risk factors included in CHA2DS2VASc score. 
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Table 1.1.6: Vitamin K antagonist use and stroke/thromboembolic event rate in non-dialysis dependent chronic kidney disease 
VKA and event rate in non-dialysis dependent CKD 
Study Study Type Number  Findings 
Lai et al (2009) 
(108) 
Observational 307 Stroke event rate (% per year): 
Dose-adjusted warfarin (INR target 2-3): 3.48 
No VKA: 13.57 
Hart et al (2011) 
(109) 
Post-hoc analysis 516 Stroke/embolic event rate (% per year): 
Dose-adjusted warfarin: 1.45 
Dose-adjusted warfarin plus aspirin: 7.05 
Olesen et al (2012) 
(92) 
Subgroup 
analysis 
3587 HR of stroke comparing with no antithrombotic NDD CKD: 
Warfarin only: 0.84 (95% CI 0.69 – 1.01) 
Warfarin plus aspirin: 0.76 (0.56 – 1.03) 
Aspirin only: 1.25 (1.07 – 1.47)   
Bonde et al (2014) 
(58) 
Retrospective 154254 non-valvular AF 
pts 
(out of which 4519 on 
NES CKD, 1130 on VKA) 
 Stroke and thromboembolic risk in non-VKA user: 
HR a: 1.31 (95% CI 1.22 – 1.41) 
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Shah et al (2014) 
(105) 
Retrospective 204 210 NES pts with 
AF (103 652 on VKA) 
Stroke risk with warfarin use in non-dialysis patient: 
HR: 0.87 (95% CI 0.85 – 0.90) 
Bleeding risk in non-dialysis patient: 
HR: 1.19 (95% CI 1.13 – 1.85) 
Providencia et al 
(2014) (110) 
Meta-analysis 19 studies – 379506 
patients with CKD and 
AF 
Stroke and thromboembolic risk in non-NES VKA user: 
HR 0.39 (95% CI 0.18 – 0.86) 
Abbreviations: CKD, chronic kidney disease; INR, international normalised ratio; NDD, non-dialysis dependent; NES, non end stage; VKA, 
vitamin K antagonist 
a Adjusted for Aspirin treatment and all risk factors included in CHA2DS2VASc score. 
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Non-VKA Oral Anticoagulants 
With the introduction of the non-VKA oral anticoagulants (NOACs), namely the direct 
thrombin inhibitor (dabigatran) and Factor Xa inhibitors (rivaroxaban, apixaban and 
edoxaban), these were considered as viable alternatives for patients with mild to 
moderate CKD requiring oral anticoagulant for thromboprophylaxis.    
All four agents [Table 1.1.7] demonstrated non-inferiority or even superiority in 
stroke prevention, and non-inferiority (or in some cases, superiority) in bleeding 
profile as compared to warfarin (117-121). Even amongst those with moderately 
reduced renal function (as low as GFR 30mL/min), apixaban and edoxaban subgroups 
of ARISTOTLE and ENGAGE AF-TIMI 38 trials had demonstrated a reduced bleeding 
risk compared to warfarin. Additional benefits include medication delivery in fixed 
doses, not requiring monitoring and a lower propensity for interaction with food or 
other medications (122, 123). 
Nonetheless, as all NOACs have a degree of renal excretion (varying from 25% in 
apixaban to 80% in dabigatran), in their respective trials, those with severe renal 
dysfunction or ESRD were excluded. Therefore, the European guidelines recommend 
that the NOACs are best not be used where severe renal impairment (GFR <25–30 
mL/min) is present (79, 124). Among those with moderately impaired renal function, 
(GFR 30 – 49mL/min), dose alteration as per manufacturer’s recommendation is 
advised. 
For patients in the USA, the FDA has approved dabigatran 75mg bid, rivaroxaban 
15mg od and apixaban 2.5mg bid for patients with a creatinine clearance of 15-
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29mL/min. That is based on no clinical trial outcome data but on pharmacological 
modelling data in patients alone. Recently, based on the latest pharmacokinetic 
findings in patients receiving  haemodialysis, the FDA has also approved the use of 
apixaban 5mg bid (no dose adjustment) in AF patients receiving chronic, stable 
dialysis treatment (125). 
A recent meta-analysis has demonstrated the relative safety and efficacy of all the 
four NOAC agents over warfarin across various degrees of renal impairment (27). 
Although there is currently no head to head clinical trial comparing one NOAC with 
another, the same analysis also revealed that in “moderate renal dysfunction” 
(creatinine clearance 25 – 49ml/min), apixaban possessed better safety profile while 
retaining similar power of efficacy in protection against thromboembolic event. 
Nonetheless, in those with “mild renal dysfunction” (creatinine clearance 50 – 79 
ml/min), dabigatran 110mg, apixaban, rivaroxaban and edoxaban 30mg are 
comparable. 
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Table 1.1.7: Randomised Controlled Trials for NOAC in atrial fibrillation 
 
Study Connolly et al (2009) 
(118) 
RE-LY 
Connolly et al 
(2011) (117) 
AVERROES 
Granger et al (2011) 
(119) 
ARISTOTLE 
Patel et al (2011) (120) 
ROCKET AF 
Giugliano et al (2013) 
(121) ENGAGE AF-TIMI 
38 
Number 18113 5999 18201 14264 21108 
Dosage Dabigatran 150 mg twice 
daily 
 
Dabigatran 110mg twice 
daily 
 
Dose-adjusted Warfarin 
Apixaban 5mg 
twice daily 
 
Aspirin 81-324mg 
daily 
Apixaban 5mg twice 
daily 
 
Apixaban 2.5mg twice 
daily (eGFR 
<50mL/min) 
 
Dose-adjusted Warfarin 
Rivaroxaban 20mg once 
daily 
 
Rivaroxaban 15mg once 
daily(eGFR 30-
49mL/min) 
 
Dose-adjusted Warfarin 
Edoxaban 60mg once 
daily 
 
Edoxaban 30mg once 
daily 
 
Dose-adjusted Warfarin 
F/U 
(months) 
24 13.2 21.6 23.5 Median F/U 2.8 years 
CKD stages 
studied 
eGFR 30-50mL/min 
eGFR 50-79mL/min 
eGFR 30-60mL/min eGFR 25-30mL/min 
eGFR 31-51mL/min 
eGFR 30-49mL/min 
eGFR ≥50-mL/min 
eGFR 30 - ≤50mL/min 
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eGFR 51-80mL/min 
Pharmacoki
netics 
80% renally excreted 25% renally 
excreted 
25% renally excreted 33% renally excreted 35% renally excreted 
Key Results 
 
(Event 
rate %/year) 
Superior to warfarin in 
reducing ischaemic 
stroke and 
thromboembolism  
(1.11 vs 1.53 vs 1.69) 
 
Non-inferior in bleeding 
events  
(3.11 vs 2.71 vs 3.36) 
Superior to 
warfarin in 
reducing ischaemic 
stroke and 
thromboembolism  
(1.6 vs 3.7) 
 
Non-inferior in 
bleeding events 
(1.4 vs 1.2) 
Superior to warfarin in 
reducing ischaemic 
stroke and 
thromboembolism 
(1.27 vs 1.6) 
 
Lower incidence of 
bleeding events 
(2.13 vs 3.09) 
Non-inferior to warfarin 
in reducing ischaemic 
stroke and 
thromboembolism 
(2.2 vs 2.4) 
 
Non-inferior in bleeding 
events 
(14.9 vs 14.5) 
Non-inferior to warfarin 
in both doses in reducing 
ischaemic stroke and 
thromboembolism 
(1.49 vs 1.91 vs 1.69) 
 
Lower incidence of 
bleeding events 
(2.75 vs 1.61 vs 3.43) 
Outcomes 
in subset 
with CKD 
No difference in primary 
outcome 
Lower stroke risk 
with no increase in 
bleeding risk 
Non-inferior in stroke 
risk, but reduced 
bleeding risk for 
eGFR >30mL/min  
No difference in primary 
outcome 
Lower bleeding risk at 
reduced dose 
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Conclusion 
Renal dysfunction and AF commonly coexist and the concurrent existence of both 
conditions result in a paradoxical increase in both thromboembolic and 
haemorrhagic risks. Several pathophysiological factors have been demonstrated to 
induce a prothrombotic state while increasing bleeding sequelae. The 
thromboembolic and haemorrhagic risks are particularly high amongst dialysis-
dependent patients with ESRD. However, at this juncture, data supporting the long-
term use of VKA for thromboprophylaxis in AF in ESRD remains limited. Any potential 
benefit conferred by VKA appears to be outweighed by a disproportional increase in 
bleeding risk (and thrombotic events). Nonetheless, potential use of specific NOAC 
(apixaban) has recently been licensed though its use in haemodialysis individuals is 
based on limited pharmacokinetic studies only. 
Conversely, the use of various oral anticoagulant (be it VKA or NOACs) among mild 
CKD patients with AF have shown a reduction in morbidity and mortality from stroke 
and systemic thromboembolism. Even in moderately impaired CKD, apixaban and 
edoxaban appear to have a good safety profile [Figure 1.1.2].  
The key would be for careful patient selection through the use of risk stratification 
scores (CHA2DS2-VASc and HAS-BLED scores). Upon initiation of oral anticoagulation 
treatment, ensure substantial steps are taken to reduce bleeding risk (such as aiming 
for a high Time in Therapeutic Range, >70%(126)) plus regular monitoring of renal 
function if NOAC is chosen so as to allow for dose alteration if needed. Patients with 
CKD and AF are prone to experience fluctuation in renal function due to acute illness 
(127), thus making timely dose alteration vital to prevent adverse events (128). 
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As a result of an increasingly older global population, the complexity of managing AF 
with concurrent CKD will appear to further increase in the future. Hence a search for 
the best pharmacological approach to prevent stroke, systemic thromboembolism 
and bleeding events is clearly needed. 
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Figure 1.1.2: Anticoagulant choice in atrial fibrillation and chronic kidney disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Limited data based on observational studies or pharmacodynamics modelling only. 
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1.2 Fibrin Clot – formation, degradation and changes in disease 
Introduction 
In the healthy human body, there is a delicate balance between fibrin formation and 
degradation. Abnormal thrombotic or haemorrhagic phenomena will occur if one of the two 
processes takes precedence over the other. 
The concept of coagulation and fibrinolysis is through the activation of pro-enzymes in a 
step-wise cascade which results in the aggregation of fibrin into fibrin clot (coagulation), or 
through the degradation of fibrin clot (fibrinolysis). In the classical coagulation cascade, it is 
subdivided into two initial pathways: the intrinsic pathway and extrinsic pathway. 
The intrinsic pathway involves kallikrein and a negatively-charged surface activating the 
surface-bound Factor XII. Factor XII in turns activate Factor XI, which subsequently activates 
Factor IX. Activated Factor IX, in the presence of activated Factor VIII, will activate Factor X. 
The extrinsic pathway involves release of tissue factor which will in combination with Factor 
VII, activate Factor X. In this common pathway of coagulation, Factor X will activate 
thrombin from inactive prothrombin, by cleaving off prothrombin fragment 1 and 2 from 
the pro-enzyme (prothrombin, Factor II). This process will end with the initiation of 
fibrinogen conversion to fibrin monomer by thrombin (Factor IIa) and subsequent lateral 
aggregation into fibrin fibre. 
Fibrinogen and Fibrin Clot formation 
Fibrinogen is a dimeric molecule consisting of identical pairs of three separate chains (Aα, 
Bβ and γ-chains), all of which are linked by disulfide bonds (129). This molecule exists as an 
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elongated 45-nm structure, circulates within the plasma at 200-450mg/dL and is generated 
by a functioning liver. It is also subdivided into three domains, one E-domain and two D-
domains, which contain binding sites that participate in fibrinogen conversion to fibrin, 
fibrin assembly, crosslinking, and platelet interactions (130) (Figure 1.2.1). 
The E –domain contains the N-termini of all the fibrinogen chain and is located at the centre 
of the dimeric molecule, whereas the D-domain located at the bilateral portion of the 
molecule, contains the C-termini of the Bβ and γ-chains. On the other hand, the C-termini of 
the Aα-chain loops back towards the E-domain. The N-termini of the Aα-chains and Bβ-
chains are named Fibrinopeptide A and fibrinopeptide B (FPA and FPB respectively), which 
will be cleaved during activation of fibrinogen to fibrin monomers. 
Figure 1.2.1: Fibrinogen and Fibrin monomer (131) 
 
Source: Putnam FW. The Plasma Proteins. 4 ed. New York: Elsevier, 2012: 127-137 
During the final stage of the coagulation cascade, the presence of thrombin will cleave off 
FPA and FPB from fibrinogen, resulting in formation of fibrin monomer. This allowsexposure 
of polymerisation sites in the E-domain (EA and EB) which will bind non-covalently with 
corresponding DA and DB sites located at the D-domain of neighbouring fibrin 
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monomer(132). These fibrin oligomers subsequently grow into a two-stranded fibrin 
protofibrils and after a certain length undergo lateral polymerisation and aggregation into 
three-dimensional fibrin fibre and fibrin bundles (133, 134). 
Thrombin, besides initiating the formation of fibrin from fibrinogen, can also activate Factor 
XIII. Factor XIII in combination with calcium will predominantly allow for formation of cross-
bridges between C-termini of γ-chains of neighbouring fibrin monomers through covalent 
bonds between a glutamine residue and a lysine residue of these neighbouring monomers; 
to a lesser extent, Factor XIII also stimulates cross-bridges between α-chains of 
neighbouring monomers (135, 136). This progressive cross-linkage involving both α-chains 
and γ-chains causes the fibrin fibres to become less susceptible to plasmin-induced 
fibrinolysis, forming insoluble fibrin, which further reinforced by the binding of several 
fibrinolysis inhibitors (all of which are induced by Factor XIII)(135). 
The formation and folding of fibrin fibres will finally allow them to acquire a three-
dimensional configuration, giving it the unique structural and biochemical properties. Fibrin 
network which are more “coarse” will result in greater opacity in light, as compared to those 
“fine” network which are more translucent. These “coarse” networks have been 
demonstrated to consist of fibres of thicker diameter and arranging in a “looser” 
configuration, as compared to the “fine” network which comprises of more fibres per 
volume of fibrin clot (137). 
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Fibrin Clot Degradation 
Similar to the coagulation cascade, the fibrinolytic process is also governed by several 
proenzymes: namely tissue plasminogen activator (tPA), urokinase plasminogen activator 
(uPA) and also Factor XII-related activations. All of which have the potential to cleave 
plasminogen to plasmin which is the key to fibrinolysis, but with tPA-related pathway being 
the most dominant(138). 
During the fibrinolysis process, fibrin-bound plasminogen will rapidly be activated by tPA. 
This induces partial degradation of fibrin cross-bridges, which further expose more sites to 
additional plasminogen, tPA, uPA and fibrinolytic enzymes, which further accelerates the 
fibrinolysis process (139). The breakdown of fibrin fibre bundles into progressively smaller 
fragments and complexes, and thus finally to D-domains (or D-Dimers/DD fragments) and E 
fragments. 
The rate of fibrinolysis can be influenced by several fibrin clot structure properties, such as 
“fine” network being more resistant to fibrinolysis than “coarse” network. Due to the laying 
down of layers of dense, thin fibre-matrix which possesses complex architecture that 
reduces permeability and thus reduces exposure of potential binding sites to tPA and 
plasminogen (139). 
Nevertheless, the processes of formation of fibrin clot and subsequent fibrinolysis are 
complex. They can be altered by subtle changes in the in vitro environment (such as 
thrombin concentration, salinity of solution, pH and ionic strength), as well as through 
pathological conditions during human disease. Hence more research is required to provide a 
better understanding of fibrin clot structure and fibrinolysis. 
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Atrial Fibrillation and Fibrin Clot Structure in Cardiovascular Diseases 
Atrial fibrillation (AF) is an atrial tachyarrhythmia characterized by rapid, chaotic and 
uncoordinated atrial activation with subsequent deterioration of atrial mechanical function. 
It is the most common cardiac arrhythmia and increasingly prevalent amongst the elderly. 
Up to 20% of ischaemic stroke is consequent to AF, and ischaemic stroke in association with 
AF is generally more severe and results in higher mortality, greater disability and longer in-
patient stay than stroke occurring in the absence of this arrhythmia (20). 
Though the main clinical issue in AF and its resultant sequelae is invariably thrombosis, the 
understanding of the effect of the three classical thrombotic factors (namely blood flow, the 
blood vessel wall, and the constituents of the blood) as described the Victorian pathologist 
Virchow are incomplete. Indeed Virchow’s triad is currently being re-interpreted as having 
roles for the endothelium (endothelial function), platelets, and the molecules of the 
coagulation cascade that generate fibrin clot (140), plus their impact on thrombosis in AF 
have yet to be fully elucidated. 
At the same time, changes in the fibrin clot structure characteristics have been 
demonstrated in patients with increased risk of established cardiovascular and thrombotic 
disease (141-145).  Fibrin clots made from these “high-risk” patients are usually thicker, 
have earlier polymerisation and are less permeable when compared with clots made from 
healthy controls (141-145). However, as AF patients are at even higher thrombotic risk than 
patients with cardiovascular diseases, the relationship between clot structure characteristics 
amongst AF patients need to be investigated. 
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Atrial Fibrillation, Renal Dysfunction and Fibrin Clot 
AF and renal dysfunction are closely interlinked. The prevalence of AF rises rapidly from 
0.7%(146) in the general population age <60, to 27% (147) amongst those with end-stage 
renal disease. This is illustrated by the Atherosclerosis Risk in Community (ARIC) Study, 
showing that patients with GFR of 60 - 89, 30 - 59, and 15 - 29 mL/min/1.73 m2 have hazard 
ratios of developing AF (within the 10 year follow-up period) of 1.3, 1.6, and 3.2, 
respectively, as compared to those with normal GFR (9). 
In addition, amongst those with renal dysfunction, the existence of several 
pathophysiological pathways also results in a prothrombotic-hypercoagulable state. Thus, in 
clinical medicine, the combination of AF and renal dysfunction creates a therapeutic 
dilemma, as thrombotic risk amongst CKD-AF patients is not completely reduced with oral 
anticoagulant but the use of oral anticoagulant among them is associated with increased 
risk of bleeding (57). Amongst patients with ESRD, previous works by Sjoland have 
demonstrated altered fibrin clot structure in haemodialysis while Undas suggested fibrin 
clot structure in ESRD may be associated with increased mortality (148, 149). However no 
relationship between progressive CKD and AF has ever been explored. 
Fibrin Clot Structure and Effects of Vitamin K Antagonist and Non-Vitamin K Antagonist 
Oral Anticoagulants 
The VKA is the classic oral anticoagulant used to reduce the risk of thromboembolic 
complications of AF. VKA reduces thrombin generation through the inhibition of coagulation 
Factors II, VII, IX and X. Nonetheless, the effect of VKA on fibrin clot structure and network 
generation, as well as subsequent fibrinolysis, have yet to be investigated. 
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However, the advent of NOACs in the past five years has completely changed the landscape 
of antithrombotic treatment. By directly and competitively inhibiting specific pathways 
along the coagulation cascade, such as Factor Xa (by rivaroxaban, rpixaban and edoxaban), 
or inhibiting thrombin (such as dabigatran), they have been shown to be as efficacious as 
VKA, and result in a lower risk of haemorrhage. The effects of NOACs on fibrin clot structure, 
function and haemostasis will be of interest. 
Conclusion 
Fibrin clot formation and degradation is a result of complex proenzyme-related pathways.  
Changes in fibrin clot structure have been demonstrated at several patient populations who 
are at-risk of thrombotic events. The impact of AF on clot structure, the associated relation 
with progressive renal dysfunction and concurrent choice anticoagulant treatment on clot 
structure can be studied to assess their potential clinical significance. 
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Section 2: Study proposal and Hypotheses to be tested 
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Aim 
To study the different aspects of fibrin clot structure and fibrinolysis in AF and its 
relationship with renal dysfunction, primarily through the assessment of the fibroelastic 
strength of clot, fibrin clot thickness and density, rate of fibrin clot built-up and fibrinolysis. 
So as to enable us to appreciate the changes in fibrin clot structure to the paradoxical 
increase in thrombotic and haemorrhagic phenomena associated with oral anticoagulation 
use in AF and CKD. 
Background 
Atrial Fibrillation (AF) results in an increased risk of ischaemic stroke and systemic 
thromboembolism. Ischaemic stroke as a result of AF is usually more debilitating and results 
in worse functional outcome than non-AF related ischaemic stroke (20). The improving 
longevity and expansion of elderly population globally is resulting in increasing incidence of 
AF and paralleled by the rise in CKD (150-152), as both conditions share similar risk factors 
(such as hypertension and diabetes (153)) which are associated with increasing age. 
Moreover, a bidirectional relationship exists between deterioration of renal function and AF 
(17), further reinforcing the close relationship of these two conditions.  
AF per se confers a prothrombotic or hypercoagulable state through numerous 
pathophysiological pathways fulfilling ‘Virchow’s triad for thrombogenesis’, as evidenced by 
abnormalities in vessel wall, abnormalities in flow and abnormalities in blood constituents 
(29). The propensity for thrombus formation is further enhanced by CKD due to additional  
changes to the flow within left atrium and left atrium appendage, damage to vessel wall and 
54 
  
subsequent endothelial dysfunction, or upwards regulation of platelet and coagulation 
factors (30, 31, 36, 43, 47, 48). 
The corner stone for management of AF is through the use of chronic oral anticoagulation, 
classically with Vitamin K antagonist such as warfarin (79). As discussed previously in Section 
1, the use of oral anticoagulant in patients with concurrent renal dysfunction is complicated 
by the lack of efficacy and also having to contend with a corresponding rise in haemorrhagic 
risk (105). Thus, this creates a therapeutic dilemma. 
Hence to better understand the reason behind these paradoxical changes to thrombosis and 
bleeding, there is a need to investigate the potential impact of renal dysfunction (in 
concurrent AF) on fibrin clot formation and fibrin clot strength.  
Traditionally, assessment of fibrin clot formation has been simply through determining the 
time taken for a clot to form from plasma such as prothrombin time and the activated 
partial thrombplastin time. Although of undoubted value, this approach has little regard for 
the roles of other endothelial/inflammatory components involved in the coagulation 
cascade, nor the physical strength of the fibrin clot formed. 
On the other hand, with respect to fibrin clot structure, there have been a number of 
publications demonstrating alterations in fibrin clot structure and clot strength in relation to 
cardiovascular disease and severe renal failure (143-145, 148, 149, 154-159).  
In accordance with previous works by Mills et al. and Collet et al., they have independently 
demonstrated that in healthy relatives of patients presenting with premature coronary 
artery disease, there is significant alteration in fibrin clot properties. The fibres formed are 
usually thicker in diameter and forming fibrin clots of lower permeability (though less 
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dense) with relative to controls (143). The fibres are also stiffer as assessed by torsion 
pendulum, and underwent slower rate of fibrinolysis ex vivo (159). These findings are also 
supplemented reports by Fatah et al. and Undas et al., confirming similar findings in patients 
with established coronary artery disease (144, 145). Thus, confirming the association 
between changes in fibrin clot structures and the increased thrombotic risk in relation to 
coronary disease. 
Subsequently, with regards to renal disease, Sjoland et al has also reported that in patients 
with ESRD, the fibrin clot made from plasma has higher clot density which is less susceptible 
to ex-vivo fibrinolysis compared to healthy control(148). These fibrin clots from patients 
with ESRD also exhibited increased fibre thickness and underwent fibrin protofibril 
formation much quicker (149). The altered fibrin clot also associated with increased 
mortality during the 3 years follow-up. Thus, these findings suggested the relationship 
regarding ERSD with changes to fibrin clot properties and worse clinical outcome. 
Therefore, from our current knowledge, we can appreciate that changes in fibrin clot 
structure can relate to increased CAD risk as well as ESRD. However, no previous work has 
been done with regards to fibrin structure and strength with regards to AF and progressive 
renal dysfunction. No previous has work has been done investigating changes to fibrin clot 
structure in relation to choice of anticoagulant or antiplatelet therapy. 
Beside investigation of changes to fibrin clot, assessment of markers of platelets activation 
and endothelial dysfunction plus microparticles will also be done. In an adult, the 
endothelium is an organ composed of 1-6 x 1013 endothelial cells, weighing approximately 
1kg and covering a surface area of approximately 4000 to 7000 m2 (160).  Its functions can 
be broadly classified into those pertaining to blood pressure control, and those relating to 
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haemostasis, and accordingly endothelial damage/dysfunction leads to hypertension and 
coagulopathy (161, 162). Hence, von Willebrand Factor (vWF) and endothelial-selectin (E-
selectin) levels, surrogates for endothelial injury/dysfunction will be assessed to investigate 
its role in CKD-AF patients. 
On the other hand, platelet activation is implicated in myocardial infarction and elevated 
levels signify increased thrombotic potential (163-166). Thus soluble platelet-selectin (p-
selectin) levels will be assessed to investigate if changes to fibrin clot structure are in any 
way related to increase in platelet activation in relation to CKD and AF. 
Subsequently, microparticles are heterogeneous vesicles, derived from cellular membrane 
where the parent cells had undergone apoptosis or activation (167, 168). Owing to the 
nature of their parent cells, different microparticles subsets possess unique composition 
and content, which vary in their hemostatic and thrombotic potentials (169-171). Thus, 
different microparticles subsets can modulate coagulation by directly facilitating formation 
of coagulation complexes or via modulation of tissue factor dependent pathways (172, 173).  
 
While microparticles levels are increased in ESRD and correspond with increased 
cardiovascular mortality (174), a contradictory relationship exists between non-valvular AF 
and levels of circulating microparticles (175, 176). A potential relationship between 
worsening degrees of non-dialysis dependent renal dysfunction and microparticles amongst 
non-valvular AF patients, as well as the subsequent effect of levels of various microparticles 
subsets has yet to be investigated.  
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Summary   
Haemostasis demands the correct balance between thrombogenesis and fibrinolysis as 
failure leads to thrombosis and haemorrhage respectively.  This failure of haemostasis may 
relate to external factors such as type and intensity of anticoagulation treatment, renal 
function and vascular/endothelial function. The present study extends previous work by 
focussing on understanding clot structure/function and the relation to pathogenesis of 
thrombogenesis in AF. 
Hence this research project will utilise thromboelastography (TEG), turbidimetric and 
fibrinolysis assay to investigate several aspects of coagulation, fibrinolysis and fibrin clot 
structure, assessment of vascular function through ELISA, flow cytometry for assessment of 
microparticles levels and finally Scanning Electron Microscopy to visualise the fibrin clot in 
detail.   
Hypothesis to be tested 
First hypothesis: Patients with AF (anticoagulation-naive) have different thrombogenesis, 
fibrinolysis and fibrin clot structure characteristics compared to patients with established 
cardiovascular disease.     
Second hypothesis: Variability in certain aspects of haemostasis in AF patients treated with 
warfarin, with abnormal indices of thrombogenesis, fibrinolysis and fibrin clot structure, can 
be explained by altered renal and/or endothelial function.  
Third hypothesis: Clot structure, function and haemostasis in AF patients before and after 
becoming therapeutically anticoagulated depends on the class of oral anticoagulant used 
(VKA versus NOACs). 
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3.1 Materials and study design 
For my First Hypothesis, I recruited subjects as followed: (i) 50 AF patients were non-OAC 
user (aspirin) with normal-mildly impaired renal function (eGFR≥60 ml/min/1.73m2), 
comparing them with (ii) 50 patients with established, stable coronary artery disease 
(defined as those who suffer from angina with over 50% stenosis of at least 1 coronary 
artery disease on coronary angiogram) who were on aspirin. 
My Second Hypothesis was tested in a case-control cross sectional study of 200 patients 
with AF on classic VKA, warfarin. There were 50 patients in four distinct quartiles depending 
on renal function as defined by their creatinine clearance as described by Cockcroft-Gault 
formula. 
The Third Hypothesis was tested in 50 patients naïve to anticoagulation, of whom 25 were 
started on warfarin, 25 on NOAC based on clinical criteria or physician’s choice. The effects 
of these drugs on clot structure and function was assessed after 4 weeks treatment. 
Compliance among NOAC users was assessed through interviews and verbal confirmation of 
adherence to treatment.  Warfarin user would have achieved stable INR through regular 
monitoring in anticoagulation clinics.  
All subjects were recruited predominantly from (and not isolated to) patients attending AF 
and cardiology clinics at City Hospital. Data collected included full clinical and demographic 
details (age, gender, ethnicity, body weight, BMI, systolic and diastolic blood pressure, 
tobacco use, family history of CVD), concurrent disease and medication history. In all cases 
full routine bloods were taken for FBC, ESR, PT (INR), APTT, U&E’s, total and HDL-cholesterol 
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and LFTs. Renal function will be defined by creatinine clearance, calculated using the 
Cockcroft-Gault equation. 
Diagnosis of heart failure was defined as a clinical syndrome consisting of typical symptoms 
(dyspnea, oedema and fatigue) and signs (pulmonary oedema and pulmonary crackles), due 
to established structural or functional cardiac abnormality (as confirmed by 
Echocardiogram) resulting in reduced cardiac output.  
Inclusion criteria: 
  Aged 18 or over, and able to provide informed, written consent 
 For AF cohort: previous or current AF established on 12-lead ECG (inclusive of 
paroxysmal or persistent AF) 
 For coronary artery disease cohort: established coronary artery disease (previous-
Myocardial infarction over 12 months ago or angina with >50% stenosis defined by 
coronary angiogram) 
 
Exclusion criteria: 
 Patients receiving renal replacement therapy/ undergoing dialysis (peritoneal or 
haemodialysis) 
 Presence of potential cofounders – significant co-existing medical conditions: 
systemic connective tissue disease, ongoing neoplasia, recent (<3 months) 
surgery or acute cardiovascular event (established myocardial infarction by 
troponin elevation or dynamic ECG-changes to ST segments), presence of a 
prothrombotic/haemorrhagic phenomenon (such as lupus anticoagulant, anti-
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phospholipid syndrome, coagulation Factor deficiencies), overt liver disease 
(deranged LFTs with/without deranged INR), deranged FBC (anaemia, 
polycythaemia, thrombocythaemia or thrombocytopaenia), acute sepsis, NSAIDs 
or oral steroids, subtherapeutic INR upon reviewAdministration of parenteral 
anticoagulant (such as low molecular weight heparin, bivalirudin), platelet 
aggregation inhibitor (abxicimab) of ADP receptor antagonists (clopidogrel, 
prasugrel or ticagrelor). 
 
3.2 Laboratory Methods 
First and foremost, adequate written consent was obtained by mysef prior to twenty mL of 
blood taken from an antecubital vein into 0.9% citrate bottle at room temperature for assay 
of coagulation, fibrinolysis, vascular function, and fibrin clot structure. Platelet-poor plasma 
was obtained after centrifugation at 3000g for 20 minutes, and aliquots of 0.5 mL were 
frozen at -70°C until assay. The plasma was the source material for a comprehensive panel 
of markers that  provided information on the following processes. Out of which five mL of 
fresh blood was kept aside for thromboelastography (TEG). 
 
3.2.1 Thromboelastography (TEG) 
Thromboelastography (TEG) is a whole-blood viscosity assay which has been widely used in 
the assessment of coagulation and fibrinolysis (177). TEG has been used previously to 
investigate patients with end-stage renal disease (178), and in patients with ischaemic 
stroke (179), but never before being used in AF subjects. 
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In this assay, 340 µL of citrated whole blood was added to a reaction cuvette, to which 20 µL 
of 0.1 M calcium chloride solution was added to reverse anticoagulation by citrate 
(Haemonetics, Lanarkshire, UK). The reaction proceeded immediately and monitored in real 
time by the analyser with results fed directly to a microcomputer. A typical TEG graphical 
printout is presented (Figure 3.2.1.1), and shows the formation of clot, the increasing 
physical strength of the developing clot on the vertical axis over time, and finally clot 
autolysis. Together with the graphical printout, 21 TEG indices are generated, of which 5 are 
selected due to their direct assessment of coagulation and fibrinolysis (namely R-time, K-
time, Angle, MA, and LY60 indices). Further explanation of these indices provided in Section 
4. 
Figure 3.2.1.1: TEG Graphical Tracing: Amplitude against Time 
 
Key: 
A, Amplitude; CI, Coagulation Index; EPL, Estimated  Potential Lysis; G, G-parameter; K, K-
time;  
LY30, Percentage of lysis 30 minutes post maximum amplitude is attained;  
MA, Maximum Amplitude; PMA, Projected maximum amplitude; R, R-time 
3.2.2 Turbidimetric Analysis and Fibrinolysis Assay 
30 minutes 
63 
  
When plasma is supplemented with thrombin, polymerisation of fibrin will occur, and this 
process can be quantitatively measured by measuring the amount of light passing through 
this intervening, clotting substance.  
In this turbidimetric assay, 25 µL of platelet-poor plasma was added to the well of a 
standard ELISA-quality 96-well microtitre plate (R&D Systems Europe Ltd, Abingdon. UK), 
followed by 75 µL of a TRIS-NaCl buffer (1.51 g Tris-HCl, 1.75 g NaCl, 200 mL distilled water). 
Coagulation was initiated by the addition of 50µL of a thrombin/calcium solution.  
The plate was immediately loaded into a Tecan Sunrise (Tecan Group Ltd, Männedorf, 
Switzerland) plate reader at 37oC programmed to measure the optical density (OD) at 
340nm every six seconds (with an intermediate two-second shaking period) for 30 minutes. 
As fibrinogen is converted to insoluble fibrin matrix, the absorbance of light will occur and 
this is demonstrated by an initial lag phase, followed by a rapid exponential increase phase 
which result from the lateral polymerisation and aggregation of protofibrils into fibrin fibre, 
finally is followed by a plateau-phase (Figure 3.2.2.1).  
The final value of the optical density at the plateau phase is directly related to the average 
size of the fibres (180), with high level of absorbance demonstrated to be directly 
proportional to larger cross-sectional area of fibrin fibres (181).  
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Figure 3.2.2.1: Turbidimetric Analysis (Triplicates of one sample) 
 
Subsequently, fibrinolysis assay calls for 75 µL of plasma to be added to the well of a 
microtitre plate. To this is added 75 µL of a Tris/NaCl/calcium buffer supplemented with 
thrombin and tPA. The plate is also immediately loaded into a Tecan Sunrise plate reader as 
for the turbidimetric assay, and data collected for 30 minutes.  
A typical graphical print-out is presented in Figure 3.2.2.2, which demonstrates change in 
OD over time as the fibrin clot is initially formed and then lysed. The data is post-processed 
to plot into line charts, and from these the rate of clot dissolution (RCD), being the slope of 
the right hand portion of the graph, and the time for 50% clot lysis (T50) can be determined. 
Structural features of fibrin clot which may contribute to fibrinolysis or suggests increase 
thrombogenic potential will be visualised by Scanning Electron Microscopy (see below).  
Nevertheless, potential limitation of turbidimetric and fibrinolysis assay is the lack of 
assessment of humoral factors contributing to thrombosis and fibrinolysis, such as levels of 
fibrinogen, PAI, TNF-α, cytokines and interleukin. 
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Figure 3.2.2.2: Fibrinolysis Assay (Triplicates of one sample) 
 
The plot shows changes in optical density as the fibrin clot forms. Triplicate plots are 
shown.  
T100% is the time to maximum absorbance, T0% is the return of the optical denity to 
near-baseline.  
T50% is (T100% - T0%)/2.  
The slope is the sharpest fall in optical density over time under the effect of exogenous 
tPA. 
 
3.2.3 Vascular/Endothelial dysfunction   
For enzyme-linked immunosorbent assay (ELISA) blood samples were centrifuged within 30 
min of collection at 1,500 g for 20 min at 4°C. The resultant plasma was then collected and 
stored at –70°C until later batch processing by ELISA to measure soluble E-selectin and 
soluble P-selectin (R&D Systems, Minneapolis, MN, USA) as per department’s protocol  
(182). 
Vascular function was be assessed by levels of endothelial products von Willebrand factor 
(vWf) and tissue plasminogen activator (tPA) (both ELISA assays) as dictated by established 
standard operating procedures (SOPs) developed in the department. 
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3.2.4 Microparticles 
For microparticle detection, platelet-poor plasma (PPP) was obtained after 20 min 
centrifugation of citrated blood at 3,000 g and further centrifugation of PPP at 13,000 g for 2 
minutes to remove residual cellular fragments to obtain platelet-free plasma (PFP). Aliquots 
of the plasmas were frozen at –70°C for subsequent batch analysis and underwent a single-
freeze thaw cycle. 
PFP was initially incubated separately for 30 min with 0.5 μg of biotinylated anti-human 
CD42b antibody (Abcam, Cambridge, UK) for platelet-derived microparticles (PMP), or 0.5 
μg of biotinylated anti-human CD31 antibody (Abcam, Cambridge, UK) for endothelial-
derived microparticles (EMP). This was followed by a second incubation with 0.25 μg of 
Streptavidin-Alexa Fluor-647nm-R-Phycoerythrin conjugate (Life Technology, Paisley, UK) for 
30 min and then diluted with 990 μl filtered PBS (final dilution 1:100).  
MP analysis was promptly performed using the Apogee A50 flow cytometer (Apogee Flow 
Systems). Polystyrene beads of 110, 200, 500 nm and 1 μm diameter (Apogee Flow Systems) 
were used to set up the MP-size gate and small-size MP defined as events with size between 
110 and 500 nm. Triplicate of measurements (Events/uL) were recorded from region of 
interest (Figure 3.2.4.1). 
Detailed instruction regarding gating selection has previously been described by 
department’s publication (183). 
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Figure 3.2.4.1 Flow Cytometry – Microparticles detection 
 
Arrowhead: Lack of excitation of MP in Region of Interest 
Arrow: Excitation of PMP-fluorochrome conjugate 
  
3.2.5 Scanning Electron Microscope (SEM) 
To assess the fibrin clot structure using SEM in University of Leeds LIGHT Institute, fibrin clot 
can be prepared using the following method. First, 25 µL of plasma is inserted into the cap 
from aliquot tubes. Small holes were drilled through the bottom of the cap and covered in 
parafilm. After initial 2 hours of incubation in a moist environment, the clot will be washed 
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several times, before being fixed with 2% gluteraldehyde and subsequently dehydrated. 
Critical point drying with CO2 in Critical Point Drying Apparatus is done prior to mounting for 
SEM.  
The scanning electron microscope (SEM) was first developed in 1935 by focusing a narrow 
beam of electrons across a sample surface by magnetic deflection. A typical SEM (Figure 
3.2.5.1) allows for a small stream of electrons to be emitted via the electron gun while 
focused on a small spot (about 5 – 10nm). The  SEM  is  maintained  under vacuum  to  
ensure  the  beam  electrons  have  minimal  interaction with any intervening gas molecules 
on their way to the sample. Several detectors are set up to pick up secondary electrons 
generated though electron-sample interactions. The varied number of secondary electrons 
released through the interaction will determine different gray-white intensity as per 
assigned at the particular scan position. This will then be post-processed by adjacent 
computer into a SEM image. 
Figure 3.2.5.1: Schematic of an Scanning Electron Microscope (184)
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Diameter of fibres within the fibrin clot can then be determined by direct measurement 
using open-source software (ImageJ programme, Rasband, National Institute of Health, 
USA). Each clot type studied was photographed in at least 5 different areas at 5,000 and 
20,000x magnifications using an FEI Quanta 200 FEG SEM (FEI, Hillsboro, OR).  
Average fibre diameters were measured from at least 20 random fibresin each sample using 
ImageJ software. A region of a micrograph is selected at random and the diameter of every 
fibre in that area is measured. This will ensure no bias towards, for example, thicker or well-
focused fibres, thus minimising any sampling effects. The operator and analyst of SEM were 
blinded to source of plasma and associated background demographics to reduce operator-
related selection bias. Unblinding procedure took place only during final data analysis.  
 
 
3.3 Statistical Analysis 
Results are expressed as mean (SD, standard deviation) or median (IQR, interquartile range). 
Data of all subjects were analysed by t-testing, one-way ANOVA or Mann-Whitney U tests 
and Kruskal-Wallis tests, with post-hoc Tukey’s analysis as appropriate:  
Gaussian distribution was assessed by plotting of histogram, assessment of skewness and 
kurtosis, subsequently checked for normality by Anderson-Darling test. Continuous data 
between two groups assessed by t-test when normally distributed or by Mann-Whitney U 
test when non-normally distributed. Continuous, normally distributed data between more 
than two groups are assessed by ANOVA (with post-hoc Tukey’s method for multiple 
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comparisons), while non-normally distributed data were assessed by Kruskal-Wallis test. 
Categorical data assessed by Chi-Square test. Correlations were performed by Spearman’s 
correlation method and all statistical calculations were performed on a microcomputer 
using commercially available statistical package (Minitab, Minitab Inc, PA, USA). A value of P 
< 0.05 was considered significant in all statistical analyses unless specified.  
Statistical methods utilised are cross-checked by statistician.  
3.4 Ethical Considerations 
The study was conducted in accordance with the declaration of Helsinki. Ethical approval 
was obtained from the National Research Ethics Service (NRES Committee Midlands), as well 
as from the Sandwell and West Birmingham Local Research Ethic Committee.  
Written consent was obtained from all patients involved in this study. Appendices (in 
Section X) contains the REC ethics approval letter, patient information leaflet and consent 
form. 
REC Reference: 13/WM/0379; IRAS ID: 134460 
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Section 4: Validation Results 
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4. Validation of laboratory methods 
 
Coefficient of Variation (CVs) of TEG, turbidimetric and fibrinolysis analysis 
As thromboelastography (TEG), turbidimetric and fibrinolysis analysis assays were all new 
techniques, extensive validation exercises had been done during assay and SOP 
development.  
My results as demonstrated in Tables 4.1 and Table 4.2. Coefficient of variations (CV) was 
calculated by the ratio of the standard deviation to the mean. A greater CV equates to 
greater variability/spread in the results thus reduces the reliability of assay used.  
For turbidimetric and fibrinolysis analysis, frozen plasma demonstrated better median intra 
and inter-assay CV at 2.8 and 5.3%, while fresh plasma intra and inter-assay CV ranges at 3.6 
and 9.9%. Whereas for TEG, the median intra and inter-assay CV for fresh whole blood at 
16.4 and 18.4%, for fresh plasma at 19.3 and 23.7%, while frozen plasma at 20.9 and 21.7%. 
In TEG,  21 indices (Table 4.3) were evaluated but only 5 clinically significant and relevant, 
independent indices were selected for analysis, namely R-time, K-time, Angle, Maximum 
Amplitude (MA) and percentage lysed at 60 minutes (LY60).  
Other validation aspects including studies of diurnal variation, exercise-related changes in 
coagulation, fresh vs frozen plasma, transiently frozen to short-term frozen plasma and time 
delay to indices of coagulation are described further below.  
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Coefficient of Variations of flow cytometry for microparticles detection 
As microparticle detection by Apogee 50 flow cytometry was well-developed in the 
department, extensive validation was not required. However, mean intra and inter-assay 
CVs for Platelet Microparticles and Endothelial Microparticles are at 18.2 and 24.6% for 
PMP, while EMP at 9.3 and 12.9%, respectively.  
 
Diurnal variation and TEG indices 
To assess if diurnal variation in coagulation indices exist, fresh blood samples were collected 
from 10 healthy volunteers within the research department every 6 hours over a 24-hour 
period, and those samples were processed by TEG. All TEG indices demonstrated to show no 
statistical difference or diurnal variation (Table 4.4). Consent Form in Appendices. 
 
Exercise and coagulation indices (assessed by TEG) 
To assess if exercise will have any impact on coagulation indices, fresh blood samples were 
obtained from 10 healthy volunteers at baseline, at peak exercise on treadmill (defined as 
85% of maximum target heart rate achieved after corrected to age and gender), 2 hours 
post-exercise, 4 hours post-exercise, 12 hours post-exercise and 24 hours post-exercise. All 
of which were processed by TEG and resultant indices obtained.  
As demonstrated by Table 4.5, peak exercise resulted only in reduction of LY60. At 2 hours 
post-exercise, it resulted in the reduction of R-time, K-time and LY60, but increased Angle 
and MA. At 4 hours post-exercise, R-time and K-time remain reduced while MA and reduced 
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LY60 remain elevated. By 12 hours post exercise, all coagulation indices as assessed by TEG 
have returned to normal, except for reduced LY60.  
 
Fresh vs frozen plasma samples for turbidimetric and fibrinolysis analyses 
As turbidimetric and fibrinolysis assay were carried out on 96-well plate and read on an 
ELISA reader, steps were taken to optimise laboratory processes to allow for batch analysis. 
Thus 15 fresh plasma samples and respective thawed frozen samples were assessed by 
turbidimetric and fibrinolysis assay, which demonstrated no statistical differences between 
all indices measured. 
 
Transiently frozen vs short-term frozen plasma samples 
To assess if duration of freezing has any impact on coagulation and fibrinolysis indices as 
assessed by turbidimetric and fibrinolysis assay, 15 plasma samples were transiently flash-
frozen in -70 degrees freezer for 1 hour before being thawed for analysis, and compared to 
respective thawed samples which were frozen for 1 week in similar freezing condition. All 
indices analysed by turbidimetric and fibrinolysis assay demonstrated no statistical 
differences between both groups. 
 
Effect of time on indices as assessed by turbidimetric and fibrinolysis analyses or TEG 
Finally, to assess if the delay between venipuncture and analysis of samples by TEG and 
turbidimetric and fibrinolysis assay, fresh blood and corresponding plasma samples were 
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collected and periodically assessed by TEG and plate assays over a 24 hour period. Results 
are illustrated on Table 4.6 and Table 4.7 
As demonstrated by Table 4.6, the turbidimetric and fibrinolysis analyses demonstrated that 
processing samples collected over time results in a progressive shortening of the lag time 
(LT), a slower rate of clot formation (RCF) but increased maximum clot density (MCD). 
Resultant clot formed over time was also demonstrated to be more resistant to lysis by tPA, 
shown by increased T50% and reduced rate of clot dissolution (RCD). 
As compared to Table 4.7, parallel TEG data were broadly speaking stable to 24 hours after 
preparation. The only index that did show a statistical change was the Angle, which 
demonstrated that fibrin samples aggregate more rapidly at 3 and 24 hours after 
preparation (both p=0.019). 
 
Discussion 
From the result of the validation exercise, several important aspects of TEG and 
turbidimetric/fibrinolysis assay have been investigated.  
Firstly, addressing the CV for TEG, the local TEG exhibited CV of similar characteristics as 
previous publication, with Anderson et al. demonstrated that depending on choice of 
indices studied, the inter-assay CVs for TEG can range from 4 – 22% (185). Moreover, it is 
known that CVs have been altered with the use of kaolin as an haemostasis accelerant in the 
accordance to TEG protocol (186). On the other hand, as for local developed turbidimetric 
and fibrinolysis assay, the demonstrated inter-assay CV is good while comparable to 
previous publications which can range from 4.9% (187) to 28.6% (188).  
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Thus based on the most reliable CV, fresh whole blood was selected for analysis via TEG, 
over the use of fresh plasma or frozen plasma. Whereas for turbidimetric and fibrinolysis 
assay, frozen plasma was selected as choice for analysis due to its excellent CV 
demonstrated and the ability to allow for batch analysis.    
Secondly, although our study showed no diurnal differences in coagulation indices when 
blood samples are assessed by TEG among 10 healthy samples, this result is incongruent to 
findings from contemporary published works involving healthy subjects: such as variation of 
over 22% in level of von Willebrand factor (vWF) over 24 hours period(189), or platelet 
activity and aggregability, levels of coagulation system markers such as Prothrombin 
fragment 1+2, Factor VIIa, and Fibrinogen which are also shown to be elevated in especially 
in the late-morning (190). This is further supported by increased incidence of cardiovascular 
events (such as myocardial infarction and sudden cardiac death) and ischaemic stroke 
among at-risk population group in the morning (191). Otherwise, the lack of diurnal 
variation may reflect the combination of small sample size studied and fairly high median CV 
(up to 24%) for thromboelastography.   
Thirdly, the reduction in R-time and K-time, together with increased in Angle and Maximum 
Amplitude as assessed by TEG post-exercise, suggested that post-exercise is associated with 
transient but significant increase in coagulation potential. This pro-coagulant state persists 
for up to 12 hours in our healthy subjects before returning to baseline. This result is in line 
with contemporary understanding regarding the relationship between acute, strenuous 
exercise and haemostatic response. Previous Norwegian studies involving 800 healthy 
young individual demonstrated that acute exercise is associated with reduced Activated 
Partial Thromboplasmin Time (aPTT) as well as increased in D-dimer levels, suggesting an 
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increased in coagulation and fibrinolytic activities post-exertion (192). That reinforced 
previous small scale study among 10 healthy adolescents, demonstrating that following 
exercise, platelet counts, aPTT, FVIII, vWF and tPA were significantly elevated in contrast to 
plasminogen activator inhibitor, which decreased significantly until 1h after exercise (193). 
Fourthly, as fresh plasma and freshly-thawed frozen plasma demonstrate no significant 
difference in indices assessed by turbidimetric and fibrinolysis assay. It is possible to use 
frozen plasma instead of fresh plasma for batch analysis. This is further supported by 
subsequent validation exercise demonstrating no difference amongst those indices between 
transiently frozen plasma and short-term frozen plasma. At the writing of the work for this 
thesis, there is yet to be any published work in this specific field. 
Finally, the validation results also demonstrated adverse effect of time on indices as 
assessed by TEG plus turbidimetric and fibrinolysis assays. This is also in line with previous 
reports by Zambroni et al(194) and Wasowicz et al(195), suggesting the stability of fresh and 
citrated blood for up to 2 hours before processing.  
A summary of the chosen 10 indices for TEG, turbidimetric and fibrinolysis assay is 
summarized and described in Table 4.8 . 
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Table 4.1: Intra- and inter- assay CV’s of turbidimetric and fibrinolysis assay indices using 
fresh plasma or frozen plasma 
 
 
 
Index  
(unit) 
 
 
Fresh plasma  
Intra-assay 
 
Fresh plasma 
Inter-assay 
 
Frozen plasma 
Intra-assay 
 
Frozen plasma 
Inter-assay 
 
 
Turbidimetric 
 
 
 
   
 
Lag time (sec) 
 
 
2.7 
 
10.3 
 
2.4 
 
6.1 
 
Rate of clot 
formation  
(OD unit/sec)  
 
9.0 
 
7.7 
 
 
5.1 
 
6.5 
 
Maximum clot 
density  
(OD unit) 
 
2.6 
 
4.9 
 
1.3 
 
2.2 
 
Fibrinolysis 
 
    
 
Rate of clot 
dissolution 
(OD unit/sec) 
 
12.0 
 
10.8 
 
3.5 
 
5.3 
 
T50% (sec) 
 
 
3.6 
 
9.9 
 
2.8 
 
5.1 
 
Median 
(IQR) 
 
 
3.6 
(2.6-10.5) 
 
9.9 
(6.2-10.5) 
 
2.8 
(1.8-4.3) 
 
 
5.3 
(3.6-6.3) 
 
Data are %. CV = coefficient of variation, OD = optical density 
IQR = inter-quartile range 
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Table 4.2: TEG intra- and inter-assay CVs 
 
Index 
(unit) 
 
 
Whole blood 
 
 
Fresh plasma 
 
 
Frozen plasma 
 
Intra  -  Inter  Intra   -  Inter Intra  -  Inter 
       
 
R (min) 
 
 
21.8 
 
16.4 
 
19.3 
 
24.5 
 
24.6 
 
29.5 
 
K (min) 
 
 
18.4 
 
24.0 
 
23.0 
 
23.7 
 
31.0 
 
26.5 
 
Angle (degrees) 
 
 
10.4 
 
14.3 
 
9.4 
 
10.0 
 
12.4 
 
11.4 
 
MA (mm) 
 
 
5.5 
 
7.8 
 
12.2 
 
8.6 
 
17.2 
 
17.0 
 
LY60 (%) 
 
 
102.5 
 
637.9 
 
73.8 
 
94.3 
 
* 
 
* 
 
Median  
(IQR) 
 
18.4 
(8.0-
62.2) 
16.4 
(11.1-
330.1) 
19.3 
(10.8-
48.4) 
23.7 
(9.3-
59.4) 
 
20.9 
(13.6-
29.4) 
 
 
21.7 
(12.8-
28.7) 
 
Data are %. *No reliable data obtained 
MA = maximum amplitude, IQR = interquartile range 
CV = coefficient of variation 
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Table 4.3: Thromboelastography (TEG) indices 
Index Function in haemostasis 
SP-time Split point time. The time from insertion of sample into TEG 
until initial clot formation. 
R-time The time from when the sample is put on the TEG until the 
first sign of clot formation (amplitude of 2 mm) is reached. 
K- time The time from the R or beginning of clot formation to a fixed 
level of clot firmness (amplitude of 20 mm) is reached. 
Angle (α) The rate of clot growth. 
MA (Maximum  
Amplitude) 
Maximum strength or stiffness (maximum shear modulus) of 
the developed clot. MA measures the strength or elasticity of 
the clot is measured in mm. 
Time to MA Time to MA, a global measurement of the dynamics of clot 
kinetics or can be described as the time needed to form a 
stable clot. 
G parameter Actual measure of clot strength, in terms of shear elastic 
modulus strength, and a derivation of A. It is measured in 
Kdyn/cm2. 
E parameter A normalized G parameter: referred to as elasticity constant. 
Thrombodynamic  
Potential Index (TPI) 
Describes the patient’s global coagulation whether the patient 
has normal haemostasis (TPI between 6 - 15), is 
hypocoagulable (TPI < 6), or is hypercoagulable (TPI >15). 
Estimated Percent Lysis The estimated percent lysis at 30 minutes after MA. 
A30 Amplitude of the TEG tracing at 30 minutes. 
CL30 Presents the values of A30 relative to MA.  
CL30 = 100 x (A30 / MA) 
LY30 Measures percent lysis at 30 minutes after MA is reached. 
A60 Amplitudes of the TEG tracing at 60 minutes. 
CL60 Presents the values of A60 relative to MA.  
CL60 = 100 x (A60 / MA) 
LY60 Measures percent lysis at 60 minutes after MA is reached. 
Clot Lysis Time (CLT) The elapsed time between MA and 2 mm amplitude or less 
post MA. 
A parameter Measures the width of the tracing at the latest time point. 
Amplitude (A) is a function of clot strength or elasticity and is 
measured in mm. 
Coagulation Index (CI) Describes the patient’s overall coagulation is the coagulation 
index derived from the R, K, MA and Angle (α) of native or 
kaolin-activated blood samples. 
Projected MA(PMA) Estimator of MA, that is, whether the MA value will achieve at 
least the lower limit of the normal value for samples treated 
with kaolin. 
Lysis Time Estimate 
(LTE) 
An estimate of CLT. LTE is derived by calculating the slope of 
the tracing and extrapolating to an amplitude of 2 mm. 
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Table 4.4 Diurnal Variation by TEG 
 Baseline 
(0600hr) 
1200hr 1800hr 2400hr 
R-time (min) 9.03 9.01 8.81 9.79 
K-time (min) 3.09 2.87 3.04 2.78 
Angle (degree) 52.3 50.7 52.3 52.7 
MA (mm) 54.7 54.6 53.6 57.4 
LY60 (%) 8.57 8.11 7.64 6.57 
 
* no statistical difference in the 5 TEG indices described 
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Table 4.5: Exercise and coagulation indices by TEG 
 Baseline Peak 
Exercise 
2 hours 
Post 
Exercise 
4 hours 
Post 
Exercise 
12 hours Post 
Exercise 
24 hours Post 
Exercise 
R-time 
(min) 
8.28 8.42 6.26* 7.41* 8.56 8.31 
K-time 
(min) 
2.51 2.70 1.54*† 1.83* 2.54 2.75 
Angle 
(degree) 
55.0 53.7 67.1* 57.4 56.4 55.6 
MA (mm) 54.3 56.2 67.8* 64.7* 52.6 54.1 
LY60 (%) 7.62 5.55* 3.64*† 5.44* 5.22* 6.94 
 
* p<0.05 compared to baseline, † p<0.01 compared to baseline 
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Table 4.6: Effect of time on indices assessed by turbidimetric and fibrinolysis assay  
 
 
Turbidimetric assay Fibrinolysis assay 
 
Time point 
(hours) 
 
 
LT 
(secs) 
 
 
RCF 
(OD/sec) 
 
MCD 
(OD) 
 
RCD 
(OD/sec) 
 
T50 
(secs) 
T = 0 540 (92) 11.4 (3.1) 0.59 (0.1) 2.7 (0.9) 132 (19) 
T + 3 535 (93) 10.3 (2.4)  0.59 (0.1) 2.6 (0.8) 143 (24) 
T + 6 535 (104) 9.5 (2.0) 0.61 (0.1) 2.6 (0.9) 143 (21) 
T + 12 449 (83) 7.5 (1.0) 0.62 (0.12) 2.4 (0.8) 173 (17) 
T +24 378 (26)* 6.3 (1.2)* 0.67 (0.12) 1.5 (0.6) 207 (22)* 
P for linear 
trend 
0.0021 0.0002 0.703 0.0332 0.0048 
 
Data are mean (standard deviation). LT = lag time, MCD = maximum clot density, RCD = rate 
of clot dissolution, RCF = rate of clot formation, T50 = time for 50% of the clot to be lysed, 
OD = optical density.  
*p<0.001 compared to baseline. 
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Table 4.7: Effect of time on indices assessed by TEG 
 
 
 
Thromboelastography (TEG) 
 
 
Time point 
(hours) 
 
 
R  
(minutes) 
 
 
K 
(minutes) 
 
Angle (degree) 
 
MA 
(mm) 
 
LY 30 
(%) 
T = 0 12.9 (4.6) 3.4 (1.5) 45.3 (9.9) 59.7 (7.3) 2.32 (1.9) 
T + 3 12.0 (3.3) 2.7 (0.8) 55.8 (9.0)* 59.7 (7.2) 2.32 (2.5) 
T + 6 10.4 (2.4) 3.2 (1.0) 51.3 (8.8) 54.2 (11.5) 3.00 (1.1) 
T + 12 10.0 (2.00) 3.2 (1.2) 48.6 (17.7) 56.8 (10.2) 2.98 (1.7) 
T +24 9.5 (2.2)* 2.7 (1.1) 55.4 (10.9)* 59.1 (6.1) 1.52 (0.5) 
P for linear 
trend 
0.0525 0.624 0.442 0.742 0.816 
 
Data are mean (standard deviation). R = Reaction time, K = K time, LY 60 = percent lysis at 60 
minutes after MA is reached, MA = Maximum amplitude.  
*p < 0.05 compared to baseline.  
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Table 4.8: Summary of chosen indices 
  
Process assessing 
TEG indices  
R - time 
(minutes) 
The time from when the sample is put on the TEG until the 
first sign of clot formation (amplitude of 2 mm) is reached. 
K - time 
(minutes) 
The time from the R time or beginning of clot formation to a 
fixed level of clot firmness (amplitude of 20 mm) is reached. 
Angle 
(degrees) 
Angle formed by the slope of a tangent line traced from the R 
time to the K time: reflects the rate at which the clot forms. 
MA 
(mm) 
Maximum amplitude of the clot dynamics, reflecting 
fibroelastic clot strength 
LY60 (%) Percentage of the clot that has lysed 60 minutes after the 
maximum amplitude achieved. 
  
Turbidimetric and Fibrinolysis 
indices 
L time 
(minutes) 
Lag time from the initiation of the test to the start of clot 
formation 
RCF 
(OD/second) 
Rate of clot formation: change in optical density over time 
from the beginning of clot formation to maximum optical 
density 
MOD 
(units) 
Maximum optical density, reflecting clot thickness 
RCD 
(OD/second) 
Rate of clot dissolution: reduction in optical density from 
maximum to the plateau phase. 
T50 (minutes) Time for 50% of the clot to lyse. 
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Section 5: Clinical Studies 
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5.1 Clot structure: Atrial fibrillation versus coronary artery disease - aspirin 
user (anticoagulation naïve) 
Abstract 
Atrial fibrillation and coronary artery disease are prothrombotic states, but they possess 
different fibrin clot profiles and lead to different clinical risks. 50 patients with atrial 
fibrillation and 50 patients with coronary artery disease were recruited, all of whom were 
taking aspirin. To assess the different fibrin clot profile and clot strength, whole blood and 
plasma samples were obtained and analysed by thromboelastography, turbidimetric and 
fibrinolysis analysis. Using thromboelastography no statistical significant difference were 
detected. However, using turbidimetric and fibrinolysis assay, atrial fibrillation confers 
greater rate of fibrin clot formation, fibrin clot formed of greater optical density, more 
resistant to fibrinolysis and requires longer time for 50% clot lysis (all p <0.005). Despite 
exposure to aspirin, atrial fibrillation confers formation of fibrin clot of greater thrombotic 
potential which are also more resistant to fibrinolysis, compared to those from coronary 
artery disease.   
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Introduction 
Patients with atrial fibrillation (AF) and coronary artery disease (CAD) are known to have 
increased thrombotic risk. Both conditions share similar risk factors, such as hypertension, 
increasing age and diabetes; both conditions also exhibited alterations in clot profile which 
increased the associated risk of thrombotic phenomena (be it stroke or myocardial 
dysfunction) (144, 145, 196-198).   
In CAD, positive changes to fibrin clot structure (increased fibrin clot permeability and clot 
lysis) have been associated with the use of prognostically beneficial medications (such as 
ACE-inhibitor, fibrates and statins)(199, 200), while adverse fibrin clot structure with 
increased fibrin network density and reduced fibrinolysis have been observed among those 
patients with failure of antiplatelet treatment(201).  While for AF, regardless of the types of 
atrial fibrillation (permanent, persistent or paroxysmal AF), fibrin clots are denser and more 
resistant to fibrinolysis as compared to control (202, 203), with subsequent modulation of 
fibrin clot structure  shown as early as day 3 after exposure to anticoagulation treatment 
(202). However, despite both conditions sharing similar comorbidities and being closely 
related to each other (204-207), they exhibit different thrombotic and thromboembolic 
profiles. Hence, to better understand thrombotic potential of AF and CAD, there is a need to 
investigate the fibrin clot structure, in the absence of oral anticoagulant. 
I hypothesized that the differences in fibrin clot structure in AF and CAD can explain the 
variation in thrombotic risk, with patients with AF exhibiting fibrin clot which has higher clot 
density and lower tendency to undergo fibrinolysis. These changes can be detected by TEG, 
turbidimetric and fibrinolysis assay. 
89 
  
Subjects and Methods 
Over the course of 18 months (January 2014 – July 2015), 50 AF patients taking only aspirin 
as antithrombotic treatment (oral anticoagulant naïve), and 50 CAD patients (taking aspirin 
only) were recruited from the cardiology clinics at the City Hospital, Birmingham.  
Definition of AF and CAD has been described previously in chapter 3. 
Exclusion criteria were age <18 years, diagnosis of valvular AF (severe rheumatic stenosis, 
metallic prosthetic valve, mitral/tricuspid ring repair), active or recent (<12 months) 
malignancy, active immunological disease, chronic liver disease, recent or chronic infections, 
chronic inflammatory disease, connective tissue disease, recent stroke/acute coronary 
syndrome (within two months), active bleeding, recent arterial/venous thrombosis or recent 
surgery, known haemophilia or thrombophilia (such as Factor V Leiden, Protein C/S/anti-
thrombin deficiency, anti-phospholipid syndrome), use of anticoagulant (including vitamin K 
antagonist, non-vitamin K antagonist oral anticoagulant, low molecular weight heparin or 
heparin) 
 
Laboratory Methods 
Citrated venous blood was collected by venepuncture and analysed for indices of 
thrombogenesis and fibrinolysis within 2 hours of collection. The TEG was used according to 
the manufacturer’s instructions. Thrombus formation and autolysis were monitored for up 
to 60 minutes after the addition of calcium to whole blood supplemented with kaolin. The 
TEG delivers numerous indices of haemostasis. Five that pertain to the initiation of 
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thrombosis were selected, the rate of thrombus formation, the physical strength of the clot 
once formed, and the rate of autolysis (Table 4.8).  
For the fibrinolysis and turbidity assay, citrated plasma was obtained from venous blood by 
centrifugation at 2500 rpm for 15 minutes. The turbidimetric and fibrinolysis assay, which 
was conducted at 37°C throughout, consists of two parts (208). Firstly, in the turbidimetric 
assay, 25μl plasma, 75μl TRIS-NaCl buffer, and 50μl thrombin were added to the wells of 96-
well micro-titre plate in triplicate. Fibrin clot formation was followed for 30 minutes in a 
micro-titre plate reader by changes in optical density. Secondly, the fibrinolysis assay 
required 75µL of plasma and 75µL of a Tris/NaCl/calcium buffer supplemented with 
thrombin and tissue plasminogen activator (tPA). The plates were immediately loaded into a 
plate reader and data collected for 30 minutes. The data from turbidimetric and fibrinolysis 
assays were post-processed by plotting into line charts, and from these, five indices were 
obtained, three pertaining to the clot formation and density, whilst two refer to fibrinolysis 
(Table 4.8). Further details of the relationship between the TEG, turbidimetric and 
fibrinolysis assays, have previously been published(208). 
Power calculations and statistical analyses 
For a power of 80% (1 – β) and a 5% level of significance (α), based on the current data 
available, n = 50 provides a power for difference of 0.5 of a standard deviation between the 
two groups. 
Following a test for statistical normality, data were expressed as a mean (± standard 
deviation, SD) or median (inter quartile range, IQR), as appropriate. Student t test was used 
for continuous data when normally distributed or Mann-Whitney U test in the case of non-
91 
  
normal distribution (such as Creatinine, K-time and LY60). Chi-square test was used to assess 
intergroup differences in categorical variables. A P- value <0.05 was considered statistically 
significant.   
 
Results 
Baseline characteristics 
AF patients did not differ from CAD patients with regards to age, gender or other basic 
demographics. When comparing concurrent comorbidity, it is unsurprising to note that CAD 
group has a higher proportion of formal diagnosis of ischaemic heart disease (100% vs 34%, 
p <0.001) and Type 2 diabetes mellitus (42% vs 16%, p < 0.001) as compared to the AF 
group. Other comorbidities including hypertension, heart failure, chronic obstructive 
pulmonary disease and cigarette use were no different between the two groups (Table 
5.1.1). There was no difference between statin, ACE-i/ARB or beta-clocker use between two 
groups.  
Laboratory indices 
However, as shown in Table 5.1.2, when assessing the haemostasis and fibrin clot 
characteristics with TEG, turbidimetric and fibrinolysis analysis, several differences between 
AF and CAD subjects can be seen. Although no difference in TEG indices(R-time through to 
LY 60%) and no difference in lag-time have been demonstrated between both groups, AF 
patients have faster rate of clot formation (39.7 OD/sec vs 30.5 OD/sec, p = 0.004), 
formation of fibrin clot with greater maximum OD (0.49 OD vs 0.38 OD, p <0.001), indicating 
faster protofibril formation and thicker fibrin fibre formation, respectively. Slower rate of 
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clot dissolution (37.8 OD/sec vs 44.5 OD/sec, p = 0.002) and longer time for 50% lysis of 
fibrin clot (266.4 sec vs 215.6 sec, p <0.001) was also observed in AF group as compared to 
CAD group, suggestive increased resistance to fibrinolysis.  
Discussion 
The current study demonstrated that in patients with AF naïve to oral anticoagulant, fibrin 
clot structures are markedly different compared to those patients with CAD. Relating to AF 
and fibrin clot structure, it is demonstrated that AF patients who are anticoagulant-naïve 
(treated with aspirin only), possesses similar R-time and Lag Time as those CAD control. That 
is due to the lack of oral anticoagulation treatment to impede coagulation pathways. More 
importantly, greater RCF and increased Maximum OD, are also accompanied with the 
reduced RCD and prolongation of T50%, all these indices suggest that AF patient without 
oral anticoagulant are at greater prothrombotic potential, and result in greater rate of 
protofibril polymerization and subsequent formation of a “coarser” fibrin clot, which is also 
more resistant to subsequent fibrinolysis by exogenous tPA.  
Though there was no prior published work  investigating fibrin clot structure in AF as 
compared to CAD group, there are several published studies involving patients with 
thrombotic (such as those with antiphospholipid syndrome, residual vein thrombosis and 
premature peripheral vascular diseases (141, 209, 210)) or prothrombotic phenomena (such 
as Type 2 Diabetes and arterial hypertension (211, 212)) demonstrating increasing 
prothrombotic fibrin clot phenotype and delay in clot lysis. Thus it can be deduced that from 
the results obtained, a prothrombotic and hypofibrinolytic state exist among anticoagulant-
naïve AF patients, as compared to CAD control. This greater propensity for thrombosis in AF 
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persists despite having fewer concurrent diagnosed diabetes (16% vs 42%) as compared to 
those with CAD.   
The inability for whole blood TEG to detect any significant differences in thrombotic 
properties may be because the resultant whole blood clots formed from both ailments are 
invariably different, with clot formed from AF patients are more fibrin rich (“red clot”) and 
CAD being more platelet rich (“white clot”) (29). Thus any increased in thrombotic 
propensity in plasma from AF may have been counterbalanced with an increased in platelet 
aggregation and activation related to CAD. Moreover, it has been demonstrated that even 
though there is increased in platelet activation in AF, the increase may not be significantly 
more that than seen with the associated vascular disease or risk factors (213). Moreover, 
the relatively high median CV associated with TEG may make it unable to detect any small 
changes in prothrombotic state. 
This study presents several limitations. Firstly, the size of the study groups is small, however, 
the number of subjects was sufficient to detect differences between AF and CAD groups 
given the results of power calculation.  
Secondly, all laboratory assessment of fibrin clot structure is done at a single time point, and 
thus there is a likelihood that fibrin clot features may change with time.  
Thirdly, this study did not differentiate types of AF (paroxysmal, persistent or permanent) as 
the duration of sustained atrial fibrillation or potential likelihood of transient sinus rhythm 
might have an impact of the fibrin clot structure. However, even though there are increased 
haemostatic factors conferring prothrombotic state in AF as compared to control , there is 
no convincing data to suggest increased prothrombotic/pro-inflammatory factor level (such 
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as von Willebrand Factor, vWF) in persistent or permanent AF compared to paroxysmal AF 
(182, 214-216). Crucially, Drabit L et al. have recently demonstrated despite paroxysmal or 
persistent AF subjects remaining in sinus rhythm, their fibrin clot still revealed increased 
fibrin clot density and reduced clot lysis time (203). Hence these data suggests that despite 
not differentiating the types of AF, the findings from current study comparing AF and CAD 
remains novel and credible. 
Fourthly, there is no measurement of associated endothelial function (such as vWF) or 
thrombin levels, as vWF is known to key component for haemostasis in vivo by affecting 
Factor VIII plasma level (217, 218) while increased thrombin level has been associated with 
increased clot lysis time in venous thrombosis(219). Moreover, elevation of vWF has been 
detected in peripheral blood and within left atrial cavity of persistent AF and paroxysmal AF 
individuals (220, 221). Thus further studies, longitudinal in design, involving assessment of 
plasma vWF and thrombin levels will be helpful in firmly establishing the causal relationship 
between AF and altered fibrin clot structure. 
In conclusion, the current study demonstrates that individuals with AF have greater 
tendency to form fibrin clots which are thicker and more resistant to lysis as compared to 
those with CAD, thus potentially explain the increased ischaemic stroke and 
thromboembolic risk associated with AF. 
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Table 5.1.1: Demographic data for patients with AF (aspirin) and CAD patients   
 AF (aspirin) CAD p - value 
N 50 50  
Age, years 74 (13.2) 70 (10.5) 0.126 
Gender 74% male 58% male 0.121 
Weight, kg 74.5 (17.4) 80.3 (18.6) 0.115 
Creatinine, umol/L 88 (75.5 – 111) 87 (72 – 99) 0.300 
Creatinine Clearance 
(Cockroft-Gault), 
mL/min 
68.1 (37.4) 79.1 (29.9) 0.106 
Coronary artery 
disease 
34% 100% <0.001 
Type 2 Diabetes 16% 42% <0.001 
Hypertension 83.7% 90.6% 0.318 
Heart Failure 20.4% 14.0% 0.415 
Chronic obstructive 
pulmonary disease 
10.2% 14.0% 0.580 
Current Smoker 6.12% 13.9% 0.207 
Medication    
ACE-i/ARB 64% 72% 0.391 
Statin 82% 90% 0.246 
Beta-blocker 64% 60% 0.680 
 
Key:  
Normal distribution – mean (SD), t-test 
Non-normal distribution – median (IQR), Mann-Whitney 
Categorical data – Chi Square test 
Angiotensin converting enzyme inhibitor, ACE-I; Angiotensin receptor blocker, ARB 
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Table 5.1.2: AF (aspirin) vs CAD – indices by TEG, turbidity and fibrinolysis 
 
 
Key:  
Normal distribution – mean (SD), t-test 
Non-normal distribution – median (IQR), Mann-Whitney 
LY60, percentage of clot lyse 60 minutes after maximum amplitude attained; MA, maximum 
amplitude; RCD, rate of clot dissolution; RCF, rate of clot formation. 
 
 
 
 
 AF (aspirin) CAD p - value 
R-time (min) 4.96 (1.51) 5.26 (1.30) 0.32 
K-time (min) 1.35 (1.0 – 1.8) 1.5 (1.2-1.8) 0.25 
Angle (degrees) 69.1 (7.2) 67.1 (6.3) 0.18 
MA (mm) 67.9 (6.3) 67.9 (5.2) 1.00 
LY 60 (%) 3.6 (2.3 – 5.2) 3.5 (1.4 – 4.6) 0.25 
Lag Time (sec) 332 (55.8) 313 (65.5) 0.17 
RCF (OD/s) 39.7 (12.1) 30.5 (15.0) 0.004 
Max OD 0.49 (0.11) 0.38 (0.08) <0.001 
RCD (OD/s) 37.8 (10.9) 44.5 (14.6) 0.0023 
Time 50% Lysis 
(sec) 
266.4 (44.5) 215.6 (36.7) <0.001 
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5.2 Clot structure in Patients with Atrial fibrillation and renal dysfunction 
Abstract 
Atrial fibrillation confers increased thromboembolic risk, which is further increased with 
concurrent diagnosis of chronic kidney disease. However, the use of warfarin against 
thromboembolism in this patient group does not provide complete protection against 
ischaemic stroke and thromboembolism while resulting in increased risk of haemorrhagic 
sequelae. Thus potential changes to fibrin clot structure and clot strength may be related to 
worsening renal function.  
200 patients with concurrent atrial fibrillation (anticoagulated with warfarin) and renal 
dysfunction were recruited. Fibrin clot structure and strength were assessed by 
thromboelastography, turbidimetric and fibrinolysis assay, while samples of fibrin clots were 
analysed by scanning electron microscopy.   
Increased fibrin clot thrombotic potential and clot strength, with paradoxical increased 
fibrinolysis, relating to worsening renal function were demonstrated.  Creatinine clearance 
(by Cockcroft-Gault equation) was strongly correlated with laboratory indices obtained, with 
subsequent regression analysis confirming creatinine clearance as a modest but 
independent predictor of changes in these laboratory indices. Representative fibrin clot 
visualized by scanning electron microscopy confirmed increased density and increased fibre 
thickness among those with worst renal function as compared to those with mildest renal 
dysfunction.  
Clinically, 2-years follow-up demonstrated increased mortality among those with worst 
renal dysfunction, with creatinine clearance and changes to fibrin clot structure (K-time) as 
independent predictors of mortality. 
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Introduction 
With the improving longevity and a subsequent increasingly elderly population, the 
frequency of atrial fibrillation (AF) and chronic kidney disease (CKD) are increasing, and are 
becoming recognized as important causes of mortality and morbidity. Furthermore, AF and 
CKD are inter-related, in that deteriorating renal function is associated with a greater than 
three-fold increased risk of developing AF, and the diagnosis of new AF in patients with CKD 
heralds the rapid deterioration of renal function (8, 18). AF per se confers a prothrombotic 
state and results in ischaemic stroke and thromboembolic events, and this increased 
thromboembolic risk is further exacerbated by worsening renal function and also amongst 
those who are dialysis dependent, and can also result in adverse clinical outcome(55-58). 
In health, a delicate balance (homeostasis) exists involving optimal activation of coagulation 
factors, subsequent formation of fibrin, and timely fibrinolysis. Several pathophysiological 
mechanisms that influence haemostasis (such as endothelial dysfunction and elevated 
coagulation factors) are altered in those with CKD, resulting in a pro-thrombotic state (43, 
44, 55). However, the relationship between CKD and the final end-product of coagulation, 
involving the formation and degradation of fibrin, and intrinsic fibrin clot properties remain 
poorly understood. In end-stage renal disease (ESRD), fibrin clots are of higher density, are 
less permeable, and are less susceptible to fibrinolysis as compared to healthy controls 
(148). Similarly, unfavorable altered fibrin clot properties have been linked to increased 
cardiovascular mortality in patients with ESRD (149). Whole blood clotting, as defined by 
thromboelastography (TEG) in patients with CKD also demonstrated increased clot stiffness 
and accelerated rate of clot formation (222). These data focus on ESRD or patients requiring 
renal replacement therapy, while the relationship between a broad spectrum of renal 
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function (ranging from normal to severely dysfunctional) and fibrin and whole blood clot 
formation, integrity and thrombolysis has not been studied.    
The risk of ischemic stroke and systemic thromboembolism in AF can be reduced by the use 
of dose-adjusted vitamin K antagonists (VKA) such as warfarin (223, 224). However, any 
benefit derived from VKA use amongst AF patients with CKD must be balanced by an 
increased rate of bleeding, especially haemorrhagic stroke amongst those with ESRD (103, 
225). Moreover, the ability to identity those whose haemostasis is out of balance will be a 
valuable clinical tool. Indeed, a paradox is evident by the increased propensity to 
thrombosis, yet bleeding risk is increased in CKD (28).  
Thus, I hypothesized that deteriorating renal function has an adverse effect on clot 
structure, fibrin clot formation and fibrinolysis in AF patients anticoagulated with warfarin.  
 
Patients and Methods 
Subjects 
Two hundred subjects with AF were recruited from routine out-patient clinics, and all had 
been taking the VKA warfarin for at least 12 weeks. Dose-adjustment for warfarin was 
managed with the aim of achieving a stable international normalised ratio (INR) between 2 
and 3. INR was determined on the day of recruitment.  
Exclusion criteria were age <18 years, diagnosis of valvular AF (severe rheumatic stenosis, 
metallic prosthetic valve, mitral/tricuspid ring repair), active or recent (<12 months) 
malignancy, active immunological disease, chronic liver disease, recent or chronic infections, 
chronic inflammatory disease, connective tissue disease, recent stroke/acute coronary 
syndrome (within two months), active bleeding, recent arterial/venous thrombosis or recent 
surgery, known haemophilia or thrombophilia (such as Factor V Leiden, Protein C/S/anti-
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thrombin deficiency, anti-phospholipid syndrome), significant abnormal haemoglobin or 
platelet count, use of non-vitamin K antagonist oral anticoagulant. Standard clinical and 
demographic data were obtained.  
A routine blood sample was taken for assess renal function, with subsequent calculation of 
creatinine clearance by Cockcroft-Gault equation (226, 227) and of estimated glomerular 
filtration rate (eGFR) according to the modification of diet in renal disease equation (1).  
The renal function and relation to clot structure was analysed as a continuous variable and 
subsequently, assessed as 4 separate quartiles (CKD Group 1 to Group 4) depending on the 
calculated Creatinine Clearance, CKD Group 1 with the best renal clearance with CKD Group 
4 with the worst. 
The project was approved by the Local Research Ethics Committee and informed written 
consent was obtained from each subject. 
Laboratory method 
Citrated venous blood was collected by venepuncture and analysed for indices of 
thrombogenesis and fibrinolysis within 2 hours of collection. The TEG was used according to 
the manufacturer’s instructions. Thrombus formation and autolysis were monitored for up 
to 60 minutes after the addition of calcium to whole blood supplemented with kaolin. The 
TEG delivers numerous indices of haemostasis. Five of which pertaining to the initiation of 
thrombosis were selected (Table 4.8).  
For the fibrinolysis and turbidity assay, citrated plasma was obtained from venous blood by 
centrifugation at 2500 rpm for 15 minutes. The turbidimetric and fibrinolysis assay, which 
was conducted at 37°C throughout, consists of two parts (208). Firstly, in the turbidimetric 
assay, 25μl plasma, 75μl TRIS-NaCl buffer, and 50μl thrombin are added to the wells of 96-
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well micro-titre plate in triplicate. Fibrin clot formation is followed for 30 minutes in a micro-
titre plate reader by changes in optical density. Secondly, the fibrinolysis assay calls for 75µL 
of plasma and 75µL of a Tris/NaCl/calcium buffer supplemented with thrombin and tissue 
plasminogen activator (tPA). The plates are immediately loaded into a plate reader and data 
collected for 30 minutes. The data from turbidimetric and fibrinolysis assays are post-
processed by plotting into line charts, and from these, five indices were obtained, three 
pertaining to the clot formation and density, whilst two refer to fibrinolysis (Table 4.8).  
To assess the fibrin clot structure in SEM, fibrin clot can be prepared using the following 
method. First, 25 µL of plasma is inserted into the cap from aliquot tubes. Small holes would 
have been drilled through the bottom of the cap and covered in parafilm. Samples were 
washed for 1 hour with 0.9% saline (w/v) and then fixed with 2% (v/v) glutaraldehyde in 
sodium cacodylate (10.7 g L-1, pH 7.40) for 2 hours. Before dehydration, samples were then 
washed further with sodium cacodylate for 1 hour. Dehydration was performed by 
immersing samples in successive dilutions of acetone for 15 minutes (30%, 50%, 70%, 80%, 
90%, 95% and 100%). Samples were critical-point dried with CO2, and sputter coated with 
platinum using a Cressington 208HR high resolution sputter coater (Cressington Scientific 
Instruments, Watford, UK). Samples were then imaged at 5000 and 20000x magnifications 
using a FEI Quanta 200 FEG Scanning electron microscope (FEI, Hillsboro, USA). Note that 
though this technique was acquired, fibrin clot formation from plasma and SEM was 
completed by experienced collaborators in University of Leeds so as to reduce operator-
dependent factors (such as level of technical expertise) and to ensure reliable results.  
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Diameter of fibres within the fibrin clot can then be determined by direct measurement 
using open-source software (ImageJ programme, Rasband, National Institute of Health, 
USA).  
Average fibre diameters were measured from at least 20 random fibres in each sample using 
ImageJ software. A region of a micrograph is selected at random and the diameter of every 
fibre in that area was measured. That will ensure no bias towards, for example, thicker or 
well-focused fibres thus minimising any sampling effects. 
The operator and analyst of SEM were blinded to source of plasma and associated 
background demographics to reduce operator-related selection bias. Unblinding procedure 
took place only during final data analysis. 
Statistical Analysis 
For a 1 – β power of 85% and a 5% level of significance (α), based on the known data, n = 96 
provides adequate power to detect a statistically significant correlation coefficient of > 0.3 
between any of three renal indices and any of the 10 haemostasis indices. In view of 
multiple analyses and the likelihood of multiple interactions between the laboratory 
methods (208), and so to ensure extra confidence, the sample size has been doubled to 200.  
Statistical analysis techniques have previously been described in Section 3. Continuously, 
normally distributed, variable data are expressed as mean and standard deviation (SD), or as 
median and interquartile range (IQR) for non-normal distribution.  Categorical data assessed 
by Chi-Square test. As the four quartiles of CKD derived from the same population as 
defined by creatinine clearance, assessment of changes in the variables across all four CKD 
quartiles was done by manual calculation of linear trend (L-statistics and t-value initially), 
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with subsequent tabulation of corresponding p-value for assessment of significance of linear 
trend.  As the focus is assessing the changes in variable against the worsening CKD quartiles, 
not between each individual CKD quartiles, thus ANOVA and post-hoc Tukey’s test were not 
utilised. 
Correlations were sought using Spearman’s method. Stepwise multivariate regression 
analysis to determine which of three renal function indices (serum creatinine, creatinine 
clearance, eGFR) were associated most strongly and independently with the haemostasis 
indices. Analyses were performed on Minitab version 17. 
 
Results 
Clinical and demographic details of the 200 AF patients are shown in Table 5.2.1, indices of 
haemostasis (as assessed on the TEG and the turbidimetric and fibrinolysis assay) in Table 
5.2.2. 
Most data from demographics and indices of haemostasis are normally distributed, besides 
age, INR and LY30. 
Regarding TEG indices, due to the similar degree of oral anticoagulation as reflected by 
similar median INR, there is no difference between all 4 CKD groups for R-time. Nonetheless, 
with worsening renal function across the 4 quartiles, TEG revealed shortening of K-time (p = 
0.025), steeper α Angle (p = 0.009), and steeper Maximum amplitude (p = 0.024). No 
statistical difference in LY30 was noted. 
Regarding the indices obtained the turbidimetric analysis, it demonstrated similar degree of 
anticoagulation also brought about similar degree of Lag Time across all 4 CKD groups. 
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However, worsening renal dysfunction across 4 quartiles was also associated with increased 
Rate of Clot Formation (p = 0.014) and greater Maximum Optical Density (p = 0.015). 
Fibrinolysis assay however revealed increasing Rate of Clot Dissolution (p = 0.016) and 
reduction in Time to 50% clot lysed (p = 0.030) with worsening renal dysfunction. 
Correlation analysis  
Relationships between the three indices of renal function (serum creatinine, eGFR and 
creatinine clearance) the haemostasis indices are shown in Table 5.2.3. Three indices 
obtained via TEG (namely K-time, angle, maximum amplitude (MA)) and four indices 
obtained via turbidimetric and fibrinolysis assay (namely rate of clot formation (RCF), 
maximum optical density (MOD), rate of clot dissolution (RCD) and time for 50% clot lysis 
T50)) were moderately (mean r>0.25, p<0.001) correlated to one or more of the renal 
function indices.  
Unsurprisingly, the eGFR correlated strongly with serum creatinine (r= -0.821) and 
creatinine clearance (r= 0.839), whilst creatinine clearance correlated strongly (r= -0.685) 
with serum creatinine (all p<0.001). INR was not related to any renal function indices. 
Multiple regression analysis 
Subsequently, stepwise multiple regression analysis was carried out to assess for other 
independent predictors for haemostasis indices (Table 5.2.4). Systolic blood pressure 
measurement, presence of diabetes mellitus, hypertension, cigarette smoking were 
included in the model due to previous publications relating to their potential of resulting in 
more adverse clot structure (201, 212, 228). Creatinine Clearance (Cockcroft Gault) was 
selected over eGFR and Creatinine based on above correlation analysis (Table 5.2.3). Age 
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and body weight were excluded from the model to prevent multiple collinearity (with 
creatinine clearance). Various haemostatic indices (namely R-time, LY30 and Lag time) which 
do not correlate to dependent variables were removed from multiple regression analysis. 
Creatinine clearance was subsequently demonstrated to independently predict subsequent 
alteration of fibrin clot structure, albeit the effect is fairly modest (R2 = 4.91% - 14.47%, p 
<0.001). Other selected demographic factors and comorbidities did not possess any 
significant impact on indices of fibrin clot structure (Table 5.2.4).  
Scanning Electron Microscopy 
SEM was utilized to assess fibrin clot structure in detail. Figure 5.2.5 shows representative 
SEM images from patient plasma with variable CKD group (Top left for CKD Group 1, Bottom 
Right for CKD Group 4) at 5,000x magnification. Qualitatively, the fibrin clot from those with 
the worst renal function appears to possess higher fibrin clot density, made of thicker fibres. 
Subsequent magnification to 20,000x magnification (Figure 5.2.6) confirms that the fibrin 
clot density is 6.8 (4.2 – 7.9) fibres per μm2 in CKD group 1 compared to 11.8 (10.4 – 14.3) 
fibres per μm2 in CKD group 4 (p <0.001). The fibre diameter in the images were also thicker 
for those with the worst renal function at 135.4 (±21.5) nm versus 99.3 (±10.5) nm in those 
with preserved renal function (p <0.001). 
Follow-up and Clinical Outcomes 
Subjects recruited were followed-up for up to 24 months, survival from recruitment was 
recorded (Figure 5.2.7). The Kaplan-Meier survival curve demonstrated early separation of 
CKD Group 4 (as early as 1st month of follow-up period) from the rest, indicating increased 
all-cause mortality risk amongst Group 4. This trend persisted throughout the follow-up 
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period. On the other hand, Table 5.2.8 shows the stepwise binary regression analysis for all-
cause mortality. Significant independent predictors of all-cause mortality were creatinine 
clearance by Cockroft-Gault equation (OR = 0.9) and K-time (OR = 1.6). Increasing age was 
not an independent predictor of all-cause mortality. 
 
Discussion 
The current study shows that in AF patients on warfarin, whole blood and fibrin clot 
properties and structure are markedly altered with progressive renal dysfunction. Fresh 
whole blood samples from patients with worsening renal function, displayed significantly 
accelerated rate of clot formation (greater K-time and angle) and increased clot stiffness 
(greater maximum amplitude) as assessed by TEG. Similarly, in plasma, turbidimetric and 
fibrinolysis indices of the rate of clot formation, the maximum density the rate of clot 
dissolution and the time for 50% of the clot to lyse are all influenced by renal function. The 
reduction of renal function and adverse clot structure is associated with increased all-cause 
mortality over time.  
The current data corroborate well with previous findings involving thromboelastography 
(222, 229) and other techniques (148, 149), demonstrating the increased final clot strength 
in those with worst renal function. However, comparing and contrasting with Holloway 
(222) and Chapman (229), we are able to demonstrate the progressive alteration in 
properties of whole blood thrombogenesis, such that more rapid rate of whole blood clot 
formation (k-time and α Angle, p = 0.025 and 0.009, respectively) associating with 
worsening renal function (from CKD stage 1 to 4).  
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Regarding fibrin clot properties, the current data is novel and will extends findings of 
previous work in ESRD by Sjoland and Undas (148, 149), by demonstrating progressive 
deterioration of fibrin clot properties by stepwise regression of renal function. 
Representative SEMs of fibrin clot structure provide further documentary evidence relating 
to the structural changes as initially described by turbidimetric analysis in the presence of 
progressive renal failure.    
However, some discrepancies exist and require consideration. Firstly, fibrinogen level has 
been demonstrated to be significantly higher in CKD (41, 43), which has been shown to lead 
to significantly faster fibrin monomer assembly rate and thus reduction in lag time (149). 
The current study, nonetheless, demonstrate no significant variation in lag time, potentially 
highlighting the overwhelming anticoagulation effect of VKA use in subjects with AF.  
Secondly, ESRD has been demonstrated to result in formation of fibrin clot comprising of 
thicker fibres which are more resilient to fibrinolysis (148, 149). Our novel data confirms the 
greater rate of fibrin monomer lateral polymerisation (Rate of Clot Formation, p = 0.014) 
progressively thicker fibre (Maximum Optical Density, p = 0.015) with worsening renal 
function, but these are more susceptible to fibrinolysis. Notably, this analysis failed to find 
any effect of renal function on the INR, although this effect may be method-specific as other 
reported, using a different method, an association between the INR and fibrin clot 
permeability and fibrinolysis (202). 
In relation to clinical outcomes, it is unsurprising that the group with the worst renal 
clearance have the highest rate of all-cause mortality over time. This has previously been 
demonstrated in several cohort studies (18, 58, 230, 231) . However, the results are the first 
to suggest the increased in rate of protofibril build-up (K-time as assessed by TEG) as an 
independent predictor of mortality in AF patients with CKD.  
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Limitation 
Several limitations were noted to this study, the principal one being that the fibrin clot, by 
definition, is not physiological, a criticism levelled at all fibrin clot data. Although fibrin clots 
formed in vitro for permeation analysis are done in static conditions, the resultant clot 
structure will be profoundly different from those in vivo due to the presence of shear force 
by blood flow (232). Although the TEG assay is formed in rotating whole blood, and the 
micro-titre plate of the turbidimetric and fibrinolysis assay is shaken/vibrated at intervals to 
simulate a form of dynamics, neither can be said to reflect flowing blood.  
With each quartile of worsening renal function, the median age of the subjects is 
progressively older, which may be associated with increased markers of inflammation (such 
as interleukin 6 and CRP) and co-morbidities, and these may influence the clot structure and 
properties (41). However, our findings reflect the real clinical world, with progressive loss of 
renal function in elderly patient groups.  
Although the fibrinolysis assay uses exogenous tPA to promote fibrinolysis, its 
concentration, although standard throughout the project, does not necessarily reflect tPA 
levels in vivo and so may not be directly physiological. 
Despite these limitations, the current study demonstrated deterioration in clot properties 
and structures over a wide range of renal function amongst anticoagulated AF patients. 
However, despite the broad result that worsening renal function has a deleterious effect on 
haemostasis, although statistically significant, these renal function indices at best account 
for at best 14.5% of the variability of the particular index of clot structure and function 
(table 5.2.4).  
Nevertheless, our data provides insights into the phenomena of persistently increased risk 
of ischaemic stroke and thromboembolism amongst CKD or ESRD patients despite successful 
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anticoagulation, and may also help to explain the increases spontaneous haemorrhagic 
episodes experienced by these patients as a result of anticoagulation. It also reinforces the 
view that renal function is an important factor in cardiovascular disease (18, 58, 233-235). 
The inability of INR to relate to renal function or clot indices indicates that there may be a 
place for the TEG and/or the turbidimetric and fibrinolysis assay to provide an individualised 
risk of thrombosis and/or haemorrhage. 
  
In conclusion, in AF patients while on warfarin, worsening renal function results in altered 
fibrin clot structure and clot properties. Accelerated clot formation and faster fibrin clot 
polymerisation despite adequate anticoagulation may explain the increased ischaemic 
stroke and thromboembolic risk in AF patients with CKD. The thicker fibrin clot formed is 
actually more sensitive to fibrinolysis in these patients also illustrate the increased risk of 
haemorrhage experienced amongst anticoagulated patients with renal dysfunction. Thus 
changes in clot structure may explain the increased mortality observed.  
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Table 5.2.1 Demographics and clinical details 
 Overall CKD  
Group 1 
CKD 
Group 2 
CKD 
Group 3 
CKD  
Group 4 
p – value 
for trend 
N 200 50 50 50 50  
Features       
Age, years 73 (11.4) 65 
(52 - 71) 
72 
(66 – 79) 
78 
(74 – 80) 
82 
(78 - 86) 
<0.001 
Gender 55% male 60% male 64% male 54% male 44% male 0.0652 
Weight, kg 83.6 (22.1) 100 (27.8) 84 (11.7) 78.7 (15.8) 69.9 (17.8) <0.001 
INR 2.5 (0.7) 2.4 
(2.1 – 3.2) 
2.5 
(2.1 – 2.8) 
2.3 
(2.0 – 2.9) 
2.4 
(1.9 – 2.9) 
0.550 
Creatinine, 
umol/L 
107 (47) 76.5 (16.5) 87.4 (14.9) 106.9 
(29.4) 
159.2 (59.8) <0.001 
Cr Cl (CG) 71 (38) 121.3 (35.2) 76.8 (5.1) 54.7 (6.9) 30.6 (8.5) <0.001 
Comorbidities   
Ischaemic 
Heart Disease 
43% 30% 42% 48% 48% 0.0546 
Type 2 
Diabetes 
Mellitus 
39% 38% 32% 38% 48% 0.5822 
Hypertension 83% 70% 86% 84% 86% 0.0614 
Heart Failure 38% 30% 32% 42% 48% 0.0371 
Chronic 
Obstructive 
Pulmonary 
Disease 
16% 18% 8% 18% 18% 0.6622 
Current 
Smoker 
3.5% 4% 0% 2% 8% 0.2284 
Medication       
Concurrent 
Antiplatelet 
6% 8% 4% 6% 6% 0.79 
Beta-blocker 76.5% 74% 80% 78% 74% 0.9406 
ACE-i/ARB 72.5% 70% 74% 72% 74% 0.7234 
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Statin 64% 64% 64% 62% 64% 0.9476 
CCB 13% 10% 14% 14% 14% 0.8508 
Diuretics 34.5% 30% 34% 32% 42% 0.2581 
Digoxin 22.5% 24% 22% 24% 20% 0.7050 
 
ACE-i, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CCB, 
Calcium channel blocker; CKD, Chronic kidney disease; INR, International normalised ratio. 
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Table 5.2.2: AF and renal dysfunction – Indices by TEG, turbidimetric and fibrinolysis assay 
 
 Overall 
Mean 
CKD  
Group 1 
CKD  
Group 2 
CKD  
Group 3  
CKD  
Group 4 
p – value for 
trend 
TEG Indices       
R-time (min) 
 
7.244 
(3.8) 
7.38 
(3.56)  
7.78 
(4.57) 
6.55 
(2.35) 
7.27 
(4.29) 
0.562  
K-time (min) 
 
1.90 
(0.95) 
2.19 
(0.54) 
2.15 
(1.49) 
1.77 
(0.74) 
1.50 
(0.55) 
0.025  
α Angle (angle) 
 
63.2 
(8.7) 
59.0  
(4.7) 
60.9 
(11.0) 
64.7 
(8.7) 
68.0 
(6.4)  
0.009  
Maximum 
Amplitude  
64.5 
(10.6) 
60.0  
(4.5) 
63.4 
(12.8)  
66.4 
(10.3) 
68.3 
(11.4)  
0.024  
LY 30 (%) 
 
0.20 
(0 – 0.6) 
0.2  
(0 – 0.7) 
0.1  
(0 – 0.6) 
0.1 
(0 – 0.5)  
0.2  
(0- 0.7) 
1.0  
Turbidimetric & 
Fibrinolysis Indices 
      
Lag Time (sec) 
 
523 
(195) 
521  
(220) 
496 
(136) 
518 
(180) 
557 
(230) 
0.371  
Rate of Clot 
Formation (OD/sec) 
17.3 
(9.6) 
13.0 
(5.6) 
16.2 
(10.1) 
18.0 
(10.0) 
22.0 
(9.9) 
0.014  
Max Optical Density 0.413 
(0.113) 
0.372 
(0.093) 
0.393 
(0.091) 
0.404 
(0.121) 
0.482 
(0.116) 
0.015 
Rate of Clot 
Dissolution (OD/sec) 
46.4 
(18.0) 
39.2  
(12.7) 
43.4 
(18.3)  
47.2 
(12.9) 
55.7 
(12.1)  
0.016 
Time for 50%  
Clot Lysis (sec) 
201.0 
(41.5) 
218.4 
(46.4) 
201.8 
(26.5) 
196.9 
(47.8) 
186.9 
(36.4) 
0.030  
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Table 5.2.3: Correlations between haemostasis indices and renal indices 
Feature Creatinine eGFR Creatinine clearance 
TEG indices    
R-time 
 
-0.033, 0.640 0.039, 0.582 0.095, 0.180 
K-time 
 
-0.271, <0.001 0.38, <0.001 0.452, <0.001 
α Angle 
 
0.251, <0.001 -0.414, <0.001 -0.487, <0.001 
Maximum 
Amplitude 
0.273, <0.001 -0.425, <0.001 -0.495, <0.001 
LY 30 
 
0.001, 0.99 -0.039, 0.58 -0.002, 0.975 
Turbidimetric & 
Fibrinolysis 
Indices 
   
Lag Time 
 
0.062, 0.385 -0.063, 0.372 -0.031, 0.662 
Rate of Clot 
Formation 
0.229, <0.001 -0.332, p<0.001 -0.338, p<0.001 
Max Optical 
Density 
0.304, <0.001 -0.332, <0.001 -0.320, <0.001 
Rate of Clot 
Dissolution 
0.361, <0.001 -0.365, <0.001 -0.342, <0.001 
Time for 50%  
Clot Lysis 
-0.258, <0.001 0.233, 0.001 0.264 <0.001 
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Table 5.2.4: Stepwise Multiple Regression Model 
 
Index 
 
 
 
 
Step 1 
p value 
 
 
Step 2 
p value 
 
Step 3 
p value 
 
R2  
(adjusted) 
 
TEG indices      
K time Cr Cl <0.001 <0.001 <0.001 9.59% 
 Systolic BP 0.52 0.58   
 T2DM 0.82    
      
Angle Cr Cl <0.001 <0.001  14.47% 
 Systolic BP 0.141    
      
Maximum 
Amplitude 
Cr Cl <0.001   7.49% 
      
Turbidimetric 
& Fibrinolysis 
Indices 
     
Rate of Clot 
Formation 
Cr Cl <0.001 <0.001  8.14% 
 Smoking 0.091    
      
Max Optical 
Density 
Cr Cl <0.001 <0.001  9.01% 
 Smoking 0.051    
      
Rate of Clot 
Dissolution 
Cr Cl <0.001 <0.001 0.001 7.75% 
 Smoking 0.055 0.5   
 T2DM 0.08    
      
Time for 50% 
Clot Lysis 
Cr Cl 0.001   4.91% 
Blood pressure, BP; Creatinine Clearance, Cr Cl; Type 2 Diabetes Mellitus, T2DM,  
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Figure 5.2.5: Representative SEM of Fibrin Clots (5,000x magnification) 
  
  
Figure 5.2.6: Representative SEM of Fibrin Clot (20,000x magnification) 
 
 
 
CKD 1 CKD 2 
CKD 3 CKD 4 
CKD 1 CKD 4 
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Figure 5.2.7: Kaplan-Meier Survival Curve for CKD Groups over time 
 
Table 5.2.8: Stepwise binary regression analysis for all-cause mortality 
 
Parameter 
 
Coefficient 
 
Standard Error 
 
p - value 
 
Odds ratio 
 
95% Confidence interval 
 
Creatinine 
Clearance 
-0.0692 0.0138 <0.001 0.9332 0.9083, 0.9587 
K - time 0.4510 0.2030 0.034 1.5659 1.0533, 2.3385 
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5.3 AF and CKD: Microparticles, soluble P-selectin, E-selectin and von 
Willebrand Factor 
Abstract 
Atrial fibrillation and chronic kidney disease are closely related, and any associated risk of 
stroke and thromboembolism due to atrial fibrillation is enhanced by concurrent renal 
dysfunction. The relationship between levels of circulating endothelial and platelet 
microparticles, and soluble P selectin (reflecting platelet activation) and E-selectin 
(reflecting endothelial activation) with progressive renal dysfunction has yet to be 
investigated.   
160 AF subjects with variable degrees of renal function were recruited. Blood samples were 
obtained, platelet and endothelial-derived microparticles were detected by flow cytometry, 
soluble P-selectin, E-selectin levels and von Willibrand factor were obtained by enzyme-
linked immunosorbent assay.   
Endothelial microparticle levels were significantly higher and demonstrated a linear trend of 
increase among those with progressively worse renal function (creatinine clearance) (p = 
0.03). Endothelial microparticles were only modestly correlated with renal function 
(creatinine clearance) (rs -0.28, p <0.001). Platelet microparticles, P-selectin and E-selectin 
levels were not significantly different across various groups of renal dysfunction, and no 
significant correlations with renal function were evident (p = 0.186, p = 0.561, p = 0.746 
respectively).  Despite modest correlation, stepwise multivariable regression analysis 
demonstrated that worsening creatinine clearance was an independent predictor of 
endothelial microparticles levels (R2 8.26%, p <0.001).  
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In well-anticoagulated atrial fibrillation patients, there is relationship between endothelial 
function (as judged by endothelial microparticle levels) and renal function.  Other markers 
of prothombotic state or cellular activation, such as platelet micriparticles, P-selectin, E-
selectin and von Willebrand factor levels were not significantly different across the various 
degree of renal dysfunction. 
 
Introduction 
 
Non-valvular atrial fibrillation (AF) is associated with an elevated risk of ischaemic stroke 
and systemic thromboembolism (236, 237). This risk is further increased by concurrent 
diagnosis of chronic kidney disease (CKD) or end-stage renal failure (ESRD) (56, 57) and 
results in a worse clinical outcome (58).  
The mechanism(s) underlying the worse outcomes in AF patients with ESRD requires further 
investigation.  Dialysis-dependent ESRD can result in increased levels of circulating 
microparticles (238). These microparticles are heterogeneous vesicles, derived from cellular 
membrane where the parent cells had undergone apoptosis or activation (167, 168). Owing 
to the nature of their parent cells, different microparticles subsets possess unique 
composition and content, which vary in their hemostatic and thrombotic potentials (169-
171). Thus, different microparticles subsets can modulate coagulation by directly facilitating 
formation of coagulation complexes or via modulation of tissue factor dependent pathways 
(172, 173).  
Even though microparticles levels are increased in ESRD and correspond with increased 
cardiovascular mortality (174), different publications have reported inconsistent results  
involving non-valvular AF and levels of circulating microparticles (175, 176). A potential 
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relationship between worsening degrees of non-dialysis dependent renal dysfunction and 
microparticles amongst non-valvular AF patients, as well as the subsequent effect on levels 
of various microparticles subsets has yet to be investigated.  
The selectins (P, E and L-selectins) mediate adhesion of haematopoietic cells to vascular 
surfaces and to each other (239, 240). P-selectin derives from α granules of platelets, as well 
as endothelial cells (241, 242) while E-selectin derives from endothelial cells activated by 
cytokines, heathy micro-vessels or as an essential component of angiogenesis (243-245). 
Hence, variations in P and E-selectin level may be present in relation to worsening renal 
function, complicated by non-valvular AF. 
In this study, the hypotheses are as followed: (i) among non-valvular AF worsening class of 
renal dysfunction is associated with a step-wise increase in microparticles, (ii) differences in 
levels of platelet-derived microparticles and endothelial-derived microparticles observed 
can be related to worsening renal function, independent of other comorbidities; and (iii) 
indices of platelet and endothelial activation plus endothelial dysfunction, as measured 
soluble P-selectin, E-selectin levels and von Willebrand Factor may be related to worsening 
renal function.  
 
Patients and Methods 
 
Subjects 
All 160 subjects with non-valvular AF were recruited from routine out-patient clinics, and all 
had been taking VKA (warfarin) for at least 12 weeks. Dose-adjustment for warfarin was 
done in specialised nurse-led anticoagulation clinic, achieving a stable international 
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normalised ratio (INR) between 2 and 3. INR was again determined on the day of testing to 
assess effective anticoagulation. 
Exclusion criteria were age <18 years, diagnosis of valvular AF (severe rheumatic stenosis, 
metallic prosthetic valve, mitral/tricuspid ring repair), active or recent (<12 months) 
malignancy, active immunological disease, pregnancy, chronic liver disease, recent or 
chronic infections, chronic inflammatory disease, connective tissue disease, recent 
stroke/acute coronary syndrome (within two months), active bleeding, recent 
arterial/venous thrombosis or recent surgery, known haemophilia or thrombophilia (such as 
Factor V Leiden, Protein C/S/anti-thrombin deficiency, anti-phospholipid syndrome), use of 
an anti-platelet agent other than aspirin, use of NOAC, and dual anti-thrombotic therapy.  
Standard clinical and demographic data were obtained.  
A routine blood test was taken to assess renal function, with subsequent calculation of 
Creatinine Clearance by Cockcroft-Gault equation (226, 227). Subsequently, all 160 subjects 
were separated into 4 quartiles (CKD Group 1 to Group 4) depending on the calculated 
Creatinine Clearance, CKD Group 1 with the best renal clearance with CKD Group 4 with the 
worst.  The project was approved by the Local Research Ethics Committee and informed 
consent was obtained from each subject. 
 
Laboratory methods 
Blood samples were collected from a large antecubital vein using a 21-gauge needle directly 
into Vacutainer® tubes (Becton Dickinson, UK) containing 0.5ml 3.2% sodium citrate.  For 
microparticle detection, platelet-poor plasma (PPP) was obtained after 15 min 
centrifugation of citrated blood at 2,800 g and further centrifugation of PPP at 13,000 g for 2 
minutes to remove residual cellular fragments to obtain platelet-free plasma (PFP). Aliquots 
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of the plasmas were frozen at –70°C for subsequent batch analysis and undergone a single-
freeze thaw cycle. 
PFP was initially incubated separately for 30 min with 0.5 μg of biotinylated anti-human 
CD42b antibody (Abcam, Cambridge, UK) for platelet-derived microparticles (PMP), or 0.5 
μg of biotinylated anti-human CD31 antibody (Abcam, Cambridge, UK) for endothelial-
derived microparticles (EMP). This was followed by a second incubation with 0.25 μg of 
Streptavidin-Alexa Fluor-647nm-R-Phycoerythrin conjugate (Life Technology, Paisley, UK) for 
30 min and then diluted with 990 μl filtered PBS (final dilution 1:100). MP analysis was 
promptly performed using the Apogee A50 flow cytometer (Apogee Flow Systems). 
Polystyrene beads of 110, 200, 500 nm and 1 μm diameter (Apogee Flow Systems) were 
used to set up the MP-size gate and small-size MP defined as events with size between 110 
and 500 nm. Detailed instruction regarding gating selection has previously been described 
(183). 
For enzyme-linked immunosorbent assay (ELISA) blood samples were centrifuged within 30 
min from collection at 1,500 g for 20 min at 4°C. The resultant plasma was then collected 
and stored at –70°C until later batch processing by ELISA to measure soluble E-selectin, 
soluble P-selectin and von Willebrand Factor(vWF) (R&D Systems, Minneapolis, MN, USA).  
(182). 
 
Statistical Analysis 
Continuously variable data are expressed as mean and standard deviation (SD) or median 
and interquartile range (IQR) dependent on normal or non-normal distribution.. Similar to 
previous chapter 5.2, assessment of  across all four CKD quartiles was done by manual 
calculation of linear trend (L-statistics and t-value initially), with subsequent tabulation of 
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corresponding p-value for assessment of significance of linear trend.   Categorical indices 
were analysed by the Chi-squared test. Correlations were sought using Spearman’s method. 
Stepwise regression analyses were performed on Minitab 17, and, in view of the multiple 
analyses, p ≤0.01 was considered as significant. 
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Results 
 
Clinical and demographic details of the 160 AF patients with concurrent CKD treated with 
VKA are shown in Table 5.3.1.  There were no significant differences in INR, gender, 
comorbidities, nicotine use or concurrent antiplatelet between all 4 quartiles of renal 
dysfunction. As expected, there was worsening renal function with lower creatinine 
clearance and higher creatinine level across the 4 CKD groups, and those with worse renal 
function are also associated with lower body weight and increased age. Of all the clinical 
demographics data, only INR is non-normally distributed, while laboratory indices are all 
non-normally distributed. 
Overall, increasing EMP levels were evident across the 4 groups of worsening renal 
clearance (p = 0.03 for linear trend) (Figure 5.3.1 and 5.3.2).   PMP levels, vWF, soluble P-
selectin and E-selectin levels demonstrated no significant difference across the 4 groups (all 
p = not significant for linear trend) (Table 5.3.2). 
There was a significant, though modest, negative correlation between creatinine clearance 
and EMP levels (Spearman, rs = 0.278, p <0.001) (Table 5.3.3). No significant correlations 
between changes in renal clearance with PMP, soluble P-selectin or E-selectin levels were 
evident (all p = not significant). However, there appears to be a trend towards negative 
correlation between creatinine clearance and vWF (Spearman, rs = 0.151, p = 0.058). 
Using stepwise regression analysis, independent predictors for EMP levels was the presence 
of worsening creatinine clearance (R2 = 8.26%, p <0.001). Other demographic factors and 
comorbidities did not any significant impact on EMP levels. 
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Discussion 
  
Among AF patients receiving oral anticoagulation, progressive worsening of renal function 
(as defined by renal clearance using the Cockcroft-Gault equation) was demonstrated to be 
associated with a linear trend for increasing levels of EMP. On stepwise regression analyses, 
renal clearance emerged as the only independent determinant of EMP levels. PMP, soluble 
P-selectin and E-selectin levels were not significantly associated with worsening renal 
function. 
AF and CKD are closely linked, and progressive renal failure is implicated in an increased 
bleeding diathesis and thromboembolic risk despite anticoagulation.  Thus, there is a strong 
need to identify potential markers that enables us to assess the decline of renal function 
and alteration(s) of thrombotic potential. 
This current finding confirms some previous studies demonstrating elevated microparticle 
levels in those with renal dysfunction/renal failure (238, 246) and contrasts with the lack of 
positive findings in other studies (247, 248) which may be due to heterogeneity among 
study subjects or resulting from smaller population size.  As EMPs are produced by 
endothelial cells in response to damage, the presence of greater vascular and endothelial 
injury associated with (or as a result of) progressive renal dysfunction will cause alteration in 
EMP levels. Hence, this study also extends previous work by demonstrating a progressive, 
step-wise, increase in EMP levels among those with worsening degrees of renal failure.  
Nevertheless, elevated EMP levels may be a surrogate of cellular injury due to 
cardiovascular diseases (249), but this can be accounted for in the study by the similar 
comorbidities between the 4 studied groups. 
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Regarding PMP, the current study demonstrates the lack of significant change in PMP levels 
in relation with worsening renal function among AF patients. Previous studies (175, 250) 
have shown that PMP levels are affected less by arrhythmia and more due to underlying 
cardiovascular diseases. Subsequently, PMP levels between AF-CKD subjects were compared 
with demographic-matched (inclusive of age and renal function), ischaemic heart disease-
CKD (IHD-CKD) control who were recruited as part of the study ), and this reveals 
significantly lower PMP levels in the AF-CKD cohort as compared to IHD-CKD control [281 
(134 – 1348) events/uL vs 7177 (1292 – 15684) events/uL, p = 0.006], further reinforcing the 
association between ischaemic heart disease and associated risk factors and PMP levels. 
The lack of alterations in soluble P-selectin and E-selectin levels across subjects with 
worsening renal function suggests that these biomarkers of platelet and endothelial cells 
activation may be less affected by other renal (dys)function. At the same juncture, the lack 
of significant increase in vWF (marker for endothelial dysfunction) with worsening renal 
function appears to run contrary to published reports (251, 252). Nonetheless, it may be 
due to cofounding factors such as chronic low level inflammation across all stages of 
CKD(49), or an over-riding elevation of vWF associated with chronic AF (215, 253, 254) may 
have outweigh the effect of progressive renal failure.   
 
Limitations 
The main limitation of this study is the lack of information regarding the potential roles of 
other microparticles besides PMP and EMP, such as those related to lymphocytes, 
leukocytes or monocyte/macrophage-derived subsets. Nonetheless, these subsets have not 
been previously related to a prothrombotic state in AF, which is the focus of this chapter.  
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Further studies should be performed to investigate their potential involvement in the 
relationship of progressive renal dysfunction and AF.   
Secondly, as this study is a single time-point sampling, changes in levels of microparticles, 
selectin levels and vWF secondary to intervention cannot be ruled out.  
In conclusion, among well-anticoagulated AF patients, there is relationship between 
endothelial function (as judged by EMPs) and renal function.  Other markers of 
prothombotic state or cellular activation, such as PMP, P-selectin, E-selectin levels and von 
Willebrand factor were not significantly different across the various degree of renal 
dysfunction. 
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Table 5.3.1 Clinical and demographic details 
 CKD Group 
1st Quartile 
CKD Group 
2nd Quartile 
CKD Group 
3rd Quartile 
CKD Group 
4th Quartile 
p – value for 
linear trend 
N 40 40 40 40  
Age, years 65 ± 11 73 ± 8 77 ± 5 81 ± 6 <0.001 
Gender 55% male 60% male 55% male 50% male 0.0652 
Weight, kg 101 (25.2) 86.3 (10.4) 81.0 (15.6) 70.4 (17.2) <0.001 
INR 2.4 
(2.2 – 3.2) 
2.5 
(2.1 – 2.8) 
2.4 
(2.0 – 3.0) 
2.4 
(2.0 – 2.9) 
0.550 
Creatinine 73.5 (16.5) 85.3 (13.8) 110.0 (30.6) 161.9 (62.8) <0.001 
CrCl (CG) 121.3 (34.7) 76.5 (4.9) 55.1 (6.7) 30.8 (8.3) <0.001 
Comorbidities      
Ischaemic Heart 
Disease 
37.5% 35% 47.5% 47.5% 0.243 
Type 2 Diabetes 
Mellitus 
40% 27.5% 42.5% 55% 0.389 
Hypertension 82.5% 90% 80% 85% 0.961 
Heart Failure 35% 30% 40% 45% 0.770 
Chronic 
Obstructive 
Pulmonary 
Disease 
20% 5% 22.5% 20% 0.741 
Concurrent 
Antiplatelet 
10% 7.5% 5% 10% 0.948 
Current Smoker 7.5% 2.5% 0% 5% 0.710 
Key: CKD, chronic kidney disease; CrCl, Creatinine Clearence; INR, International Normalised 
Ratio  
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Table 5.3.2 Microparticles, P-selectin and E-selectin levels in patients with various 
degree of renal dysfunction 
 CKD Group 1 CKD Group 2 CKD Group 3 CKD Group 4 p – value for 
linear trend 
Platelet 
Microparticles 
(Event/uL) 
281  
(134 – 1348) 
2123 
(324 – 4079) 
1476 
(82 – 5041) 
209  
(29 – 2043) 
0.897 
Endothelial 
Microparticles 
(Event/uL) 
5181 
(737 – 12352) 
6520 
(4222 – 11667) 
6095 
(415 – 24446) 
21048 
(6429 – 
29712) 
0.034 
Soluble P-selectin 
(ng/mL) 
9.09  
(7.31 – 11) 
8.97  
(7.58 – 10.4) 
9.12 
(7.19 – 11.4) 
8.28 
(6.18 – 10.8) 
0.368 
Soluble E-selectin 
(ng/mL) 
39  
(29 – 105) 
39  
(27 – 74) 
43  
(29 – 63) 
39  
(26 – 45) 
0.930 
Von Willebrand 
Factor 
(IU/dL) 
117.3 
(84.4 – 145.4) 
126.9 
(86.1 – 146.5) 
121.6 
(81.7 – 151.4) 
135.4 
(102.3– 171.7) 
0.288 
 
CKD, chronic kidney disease  
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Table 5.3.3 Spearman correlations between Creatinine Clearance and microparticles, P-
selectin, E-selectin levels and von Willebrand Factor 
 rs p 
Platelet Microparticles 0.105 0.186 
Endothelial Microparticles -0.278 
<0.001 
Soluble P-selectin 0.046 0.561 
Soluble E-selectin 0.026 0.746 
Von Willebrand Factor -0.151 0.057 
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Figure  5.3.1 Endothelial Microparticles vs CKD Group 
 
Figure 5.3.2 Excerpts of EMP Flow Cytometry Printout  
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5.4 Clot Structure in AF: Effects of Warfarin and NOACs 
Abstract 
Non-Vitamin K antagonist oral anticoagulants (NOACs) have several advantages over 
warfarin as an oral anticoagulant for thromboprophylaxis in atrial fibrillation. However, little 
is known about their potential effects on fibrin clot structure and clot strength. 
Furthermore, effect of clot structure pre- and post-exposure to oral anticoagulant in “real 
patient cohort” have not been assessed. 
82 patients on NOACs, 50 on warfarin and 41 on aspirin only were recruited. Their whole 
blood and plasma samples were analysed by thromboelastography, turbidimetric and 
fibrinolysis assay. 
Of the 41 patients who were naïve to oral anticoagulant, 10 of whom were started on 
warfarin and 10 others on apixaban. The blood and plasmas samples were analysed at 4th 
and 12th week post-exposure to oral anticoagulant. 
Anticoagulation with NOACs confers slower formation of fibrin clot which are more sensitive 
fibrinolysis, and formation of whole blood clot which underwent greater autolysis. Whereas 
aspirin are generally result in greater thrombotic and lower fibrinolytic potential as 
compared to warfarin or NOACs. Of those receiving NOACs, differences in several laboratory 
indices exist between each agent used (i.e. apixaban, rivaroxaban and dabigatran). 
Post-exposure to oral anticoagulant also result in formation of blood clot and fibrin clot 
which are more “favorable”, by demonstrating features of less thrombotic potential and 
more sensitive to fibrinolysis. 
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Introduction 
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has 
fundamentally changed clinical practice in the use of oral anticoagulation therapy in the 
prevention of ischaemic stroke and thromboembolism in atrial fibrillation (AF). Unlike 
vitamin K antagonists (VKAs, such as warfarin), which non-specifically suppress hepatic 
production of functional coagulation Factors II, VII, IX and X by inhibiting vitamin K 
metabolism (255), NOACs target specific molecules of the coagulation cascade: dabigatran is 
a direct thrombin inhibitor whilst apixaban, rivaroxaban and edoxaban target Factor Xa 
(118-121).   
NOACs have several advantages over VKAs: they possess a predictable pharmacological 
profile thus can be given at a fixed dose, have lower propensity for interactions with food or 
medication and their predictable pharmacokinetics allows for elimination of routine 
anticoagulation monitoring (124, 256, 257). More importantly, clinically trials of NOACs 
compared to warfarin, have demonstrated lower risk of intracranial haemorrhage and may 
result in lowering overall mortality.  
Nonetheless, little is known about the potential effect of NOACs on the fibrin clot structure 
or fibroelastic strength of whole blood clot. There are no previous study investigating 
potential changes to the clot structure in AF patients before and after exposure to NOAC, or 
comparing it between NOACs.  
Moreover, in the event of bleeding diathesis secondary to NOACs or suspected overdose, 
classical laboratory tests (such as the prothrombin time and the activated partial 
thromboplastin time) lack sensitivity and specificity to detect any effect of anticoagulation 
(258, 259). Other more specific assays (such as ecarin clotting time and anti-Factor Xa 
activity) are not routinely available, can be costly and lack standardization between 
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laboratories (260-263). Thus, TEG and turbidimetric-fibrinolysis assays may potentially 
provide a novel perspective on the actions of these agents. 
Therefore, we hypothesized that the TEG, turbidimetric and fibrinolysis assays will 
demonstrate difference in indices of clot formation, integrity and lysis between blood and 
plasma from AF patients taking aspirin, warfarin and the three commonly used NOACs 
(namely Dabigatran, Apixaban and Rivaroxaban).  
Secondly, among those who are naïve to oral anticoagulant, there will be difference in 
haemostasis indices post exposure to oral anticoagulant. 
 
Patients and Methods 
Subjects 
Patients with AF taking oral anticoagulants were recruited from routine out-patient 
cardiology clinics, and all had been taking their anti-thrombotic for at least 4 weeks. Doses 
were according to UK guidelines, e.g. apixaban 5 mg BD, dabigatran 150 mg BD, rivaroxaban 
20 mg OD while warfarin titrated to achieve an international normalised ratio (INR) between 
2 and 3.  For those on warfarin, INR was determined on the day of testing to assess effective 
anticoagulation. For those receiving NOACs, venepuncture took place 4 – 6 hours after the 
daily dose of the drug.  
For patients with AF who are naïve to oral anticoagulants, those taking aspirin (as only 
antiplatelet agent) were recruited. They were prescribed oral anticoagulant based on their 
personal preference or clinical requirement. Venepuncture will be done on day of 
recruitment, and subsequently be followed up in 4 and 12 weeks post exposure to oral 
anticoagulant.  
Exclusion criteria had previously been shown in Chapter 3. 
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Standard clinical and demographic data were obtained, and a routine blood test was taken 
for renal function. The project has been approved by the Local Research Ethics Committee 
and informed consent was obtained from each participant. 
 
Laboratory methods 
Laboratory methods involving TEG, turbidimetric and fibrinolysis assays have previously 
been described in Chapter 3. 
 
Statistical analysis 
Continuously variable data are expressed as mean and standard deviation (SD) or median 
and interquartile range (IQR) dependent on distribution. Differences between various NOAC 
agents and three main antithrombotic treatments were analysed by analysis of variance. 
Differences between warfarin and NOAC group were analysed by Student t test for 
continuous data when normally distributed or Mann-Whitney U test in the case of non-
normal distribution. Chi-square test was used to assess intergroup differences in categorical 
variables. A P - value <0.05 was considered statistically significant.  Analysis was performed 
on Minitab 17. 
Results 
VKA vs NOAC 
Basic clinical demographics of warfarin and NOAC users are illustrated in Table 5.4.1. 
Overall, there was no significant demographic difference between warfarin and various 
NOAC users regarding age through renal function. Relating to comorbidities, only ischaemic 
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heart diseases demonstrate a significant difference between groups, with apixaban user 
having the lowest established history of coronary disease. 
Nonetheless, when comparing warfarin and NOACs in accordance to investigative methods, 
NOACs in general bring about greater percentage of autolysis of whole-blood clot as 
assessed by TEG, and longer Lag-time plus shorter time for 50% lysis of fibrin clot when 
assessed by turbidimetric and fibrinolysis assay (Table 5.4.2).  
When comparing whole blood and fibrin clots made from three antithrombotic treatments, 
aspirin treatment resulted in changes in thrombosis as assessed by TEG: shorter R-time, K-
time, and steeper α-angle; and several changes to fibrin clot structure as assessed by 
turbidity and fibrinolysis asses: shorter Lag-time, faster rate of clot formation, greater 
Maximum Optical Density, and longer time for 50% lysis of fibrin clot. 
Contrasting between individual NOACs (Table 5.4.3), only 1 of the TEG indices differed 
between the NOACs, with shorter R-time in those on apixaban than in those of dabigatran. 
However, when using turbidimetric and fibrinolysis assays, Lag-time was shorter with 
greater Maximum Optical Density in those on apixaban or rivaroxaban, than in those 
subjects partaking dabigatran. The Rate of Clot Formation was slower in those on 
rivaroxaban than in the two other NOACs. The Rate of Clot Dissolution was slower in those 
on rivaroxaban than in those on apixaban. 
Post oral anticoagulant exposure 
For patients who were naïve to oral anticoagulation, their risk of stroke was stratified 
according to theCHA2DS2VASc score and they werestarted on appropriate oral anticoagulant 
according to physician or patient choice and clinical needs.  
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Out of which, 20 patients completed 2 subsequent follow-ups at 4th and 12th weeks. 
Differences in fibrin clot structure as assessed by TEG, turbidimetric and fibrinolysis analysis 
pre-exposure, 4 weeks and 12 weeks post exposure to oral anticoagulants are shown in 
Table 5.4.4. With regards to TEG, post-exposure to oral anticoagulation led to a 
prolongation of R-time, K-time and less steep α-angle. Whereas turbidimetric and 
fibrinolysis assay revealed a longer lag-time, lower rate of clot formation, greater rate of clot 
dissolution and shorter time for 50% lysis of fibrin clot. 
Of the 20 patients who have completed 12th weeks follow-up, 10 were taking warfarin and 
the rest apixaban. There is no statistical difference between these 2 groups regarding basic 
demographics and comorbidities. However, differences in the fibrin clot structure post-
exposure to warfarin (classic VKA) and apixaban (NOAC) are shown in Table 5.4.5, with 
warfarin user demonstrating lower rate of clot formation and higher tendency to form clots 
of greater maximum optical density. 
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Discussion 
In this study, the whole blood clot and fibrin clot structure formed from VKA and NOAC 
users possessed several structural differences. Using TEG, turbidity and fibrinolysis assays, 
some structural differences (and similarities) can be demonstrated from whole blood and 
fibrin clots formed from NOAC users as compared to VKA users.  
Firstly, NOAC resulted in similar degree of delay in the initiation of coagulation as well-
controlled VKA user, as shown by similar R-time. However, the effect on the fibrin clot per 
se (devoid of activated platelets in platelet poor plasma) is potentially more profound, and 
thus led to a prolongation of Lag-time. Moreover, the resultant whole blood and fibrin clot 
structure (as influenced by NOAC) is also less resistant to autolysis and ex vivo fibrinolysis by 
tPA, as demonstrated by changes in LY60(%) and T50. This increased susceptibility to 
fibrinolysis is consistent with previous findings involving dabigatran and rivaroxaban (264, 
265).   
Unsurprisingly, for AF patients who are not anticoagulated, and only receiving aspirin as 
antithrombotic agent, they exhibited increased tendency for thrombogenesis as 
demonstrated by shorter R-time and Lag-time (time to initiation of coagulation and fibrin 
clot formation), steeper angle, K-time and greater RCF (relating to fibrin clot 
polymerisation), thicker fibre (as reflected by greater optical density) and more resistant to 
fibrinolysis (longer time for 50% clot lysis).  
Within NOAC groups, numerous structural changes have been detected: dabigatran confers 
the greatest delay to initiation of fibrin clot formation (Lag-time) and thinnest fibre (lowest 
maximum optical density), rivaroxaban confers greatest impact in reducing the rate of 
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thrombogenesis (lowest rate of clot formation), while apixaban allows for formation of 
fibrin clot most susceptible to fibrinolysis (highest rate of clot dissolution). These may 
provide some explanation for the perceived superiority of dabigatran at reducing 
thromboembolic events. Nonetheless, these results do not explain the reduced 
haemorrhagic risk associated with NOAC uses, as increased susceptibility to fibrinolysis may 
not only allow for revascularisation (and establishment of circulation) but also increased 
haemorrhagic risk. 
When comparing pre and post-exposure blood and plasma results, the effect of oral 
anticoagulation on the whole blood and fibrin clot structure is unequivocal, as the 
transformation of “adverse clot structures” to one that possess less thrombotic potential, 
demonstrated by changes in rate of fibrin/clot built-up and increased sensitivity to 
fibrinolysis. These would explain the modulation of ischaemic stroke and thromboembolic 
risk shortly after successful anticoagulation therapy. Nonetheless, due to the small number 
of follow-up in both warfarin and apixaban cohorts, the lack of differences in clot structure 
between both groups may be a false negative error. 
Limitation 
Although the strength of this study on the fairly large number of patients recruited (n >130) 
with suitable oral anticoagulant, the lack of demonstrable differences between each NOAC 
agent as detected by TEG could be due to smaller cohort in apixaban and dabigatran groups. 
The aforementioned study (266) also utilised blood samples from healthy volunteers spiked 
with anticoagulant, as compared to “real-life” patients who may not be fully compliant to 
treatment regime, thus resulting in the lack of difference detected using TEG in the 
population studied.  
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Therefore, head-to-head comparison between NOAC agents will not be possible, and further 
work is warranted. 
In conclusion, this study is able to demonstrate structural and mechanistic differences in 
whole blood and fibrin clot structure involving NOAC and OAC, as well as between each 
commonly prescribed NOAC agents. Changes in fibrin clot and whole blood clot structure 
pre and post exposure to oral anticoagulant have also been shown. 
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Table 5.4.1 Clinical demographics – Warfarin and NOACs 
  
Warfarin 
(n=50) 
 
Apixaban 
(n=17) 
 
Dabigatran 
(n=19) 
 
Rivaroxaban 
(n=46) 
 
p - 
value 
Age  
(years) 
73.9 
(9.0) 
76.9 
(10.6) 
73.9  
(9.3) 
71.6  
(8.6) 
0.226 
Sex 
(male/female) 
32/18 8/9 15/4 26/20 0.208 
SBP  
(mm Hg) 
130 (19) 135 (18) 126 (22) 132 (18) 0.513 
DBP 
 (mm Hg) 
73 (12) 76 (15) 73 (15) 73 (11) 0.839 
BMI  
(kg/m2) 
29.6 (4.3) 27.5 (5.4) 26.7 (4.4) 30.1 (7.3) 0.097 
Creatinine 
(µmol/L) 
87 (15) 86 (30) 90 (22) 89 (22) 0.944 
Creatinine 
Clearance -
Cockcroft Gault 
(ml/min/1.73) 
77 (10) 74 (19) 72 (14) 82 (15) 0.580 
IHD  
(yes/no) 
21/29 3/14 6/13 8/38 0.041 
Smoking 
(yes/no) 
1/49 0/17 1/18 3/43 * 
Diabetes 
(yes/no) 
16/34 6/11 3/16 12/34 0.506 
Hypertension 
(yes/no) 
43/7 15/2 14/5 33/13 0.241 
Heart failure 
(yes/no) 
15/35 1/16 1/18 10/36 0.051 
Valve disease 
(yes/no) 
3/47 0/17 0/19 3/43 * 
Pulmonary 
disease (yes/no) 
4/46 3/14 1/18 5/41 0.602 
Data presented as mean (standard deviation) or number of patients. P values by analysis of variance or 
the chi-squared test.  
* = analysis unreliable. 
Body Mass Index, BMI; Diastolic blood pressure, DBP; Ischaemic Heart Disease, IHD; Systolic Blood 
Pressure, systolic blood pressure. 
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Table 5.4.2 : Analysis according to anticoagulant classes (VKA vs NOAC) and antithrombotic agents 
(VKA vs NOAC vs Aspirin) 
 
 
Data presented as mean (standard deviation) or median (interquartile range). P values analysed by the t-
test, the Kruskall-Wallis test or analysis of variance. 
Between group analysis by Tukey’s post-hoc test: 
*p<0.05 between Aspirin and two other groups 
†p<0.05 between Warfarin and two other groups 
 
 
 NOAC  
(n=82) 
Warfarin  
(n=50) 
p – value 
(NOAC vs VKA) 
Aspirin 
(n = 41) 
P – value 
(NOAC vs VKA vs 
Aspirin) 
Clinical and 
demographic 
     
Age (years) 73.5 (10.3) 71.6 (8.6) 0.234 73.2 (13.2) 0.571 
Sex (male/female) 49/33 32/18 0.627 30/11 0.343 
Creatinine Clearance 
(Cockcroft-Gault) 
78 (36) 77 (5) 0.801 73 (37) 0.753 
Creatinine  88 (24) 87 (15) 0.815 94 (45) 0.491 
      
TEG Indices      
R (min) 8.6 (4.0) 7.8 (4.6) 0.291 4.9 (1.5) <0.001* 
K (min) 1.8 (1.47-2.2) 1.8 (1.5-2.3) 0.465 1.3 (1.15 – 1.7) 0.003* 
Angle (degrees) 63.1 (8.2) 60.9 (11.0) 0.228 69.2 (6.0) <0.001* 
MA (mm) 65.3 (7.3) 63.4 (12.8) 0.339 67.2 (5.2) 0.122 
LY60 (%) 3.3 (1.8-5.2) 2.0 (0.9-3.5) 0.005 3.7 (2.55 – 5.4) 0.004† 
      
Turbidimetric & 
Fibrinolysis Indices 
     
Lag time (min) 9.6 (7.8-13.0) 8.3 (6.8-9.5) <0.001 5.3 (4.7-5.8) <0.001* 
RCF (units/sec) 15.5  
(9.6 - 26.2) 
14.3  
(9.5 - 21.6) 
0.241 39.7  
(36.3 - 44.4) 
<0.001* 
MOD (units) 0.39 (0.13) 0.39 (0.09) 0.726 0.49 (0.10) <0.001* 
RCD (units/sec) 41.4 (16.5) 43.4 (18.3) 0.194 37.7 (10.2) 0.269 
T50 (min) 3.0 (0.7) 3.4 (0.4) <0.001 4.4 (0.8) <0.001* 
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Table 5.4.3 : Analysis according to NOAC classes 
 Apixaban  
(n=17) 
Dabigatran 
(n=19) 
Rivaroxaban 
(n=46) 
p - value 
Clinical and 
demographic 
    
Age (years) 76.9 (10.6) 73.9 (9.2) 72.1 (10.6) 0.262 
Sex (male/female) 8/9 15/4 26/20 0.119 
Creatinine Clearance 
(Cockcroft-Gault) 
49.0 (41.0 – 99.5) 72.0 (53.3 – 83.4) 75.7 (54.0 – 97.1) 0.550 
Creatinine (µmol/L) 86 (30) 90 (22) 88 (21) 0.879 
     
TEG Indices     
R (min) 6.7 (1.6) 10.7 (5.9) 8.5 (3.2) 0.009a 
K (min) 1.7 (0.6) 2.2 (0,9) 2.0 (0.8) 0.175 
Angle (degrees) 64.4 (8.4) 60.9 (7.9) 63.5 (8.2) 0.371 
MA (mm) 66.2 (6.5) 64.7 (5.8) 65.1 (8.1) 0.828 
LY60 (%) 3.0 (1.4-4.2) 3.7 (2.0-6.1) 3.25 (1.8-4.9) 0.772 
     
Turbidimetric & 
Fibrinolysis Indices 
    
Lag time (min) 8.0 (7.6-9.2) 23.0 (9.8-30.3) 9.8 (7.8-12.1) <0.001b 
RCF (units/sec) 22.0 (20.0-29.0) 28.5 (16.2-30.7) 12.4 (7.0-15.3) <0.001c 
MOD (units) 0.37 (0.09) 0.27 (0.09) 0.44 (0.13) <0.001b 
RCD (units/sec) 51.8 (13.9) 42.6 (12.1) 36.8 (17.3) 0.005d 
T50 (min) 2.9 (0.45) 3.3 (0.37) 2.9 (0.75) 0.161 
 
Data presented as mean (standard deviation) or median (interquartile range). P values by analysis of 
variance or the Kruskall-Wallis test.  
Between group analysis by Tukey’s post-hoc test: 
 a p<0.05 between apixaban and dabigatran. 
 b p<0.05 between dabigatran and the two other groups. 
c p<0.05 between rivaroxaban and the two other groups.  
d p<0.05 between apixaban and rivaroxaban. 
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Table 5.4.4: Pre and Post exposure to oral anticoagulation 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean (standard deviation) or median (interquartile range). P values as assessed for 
trend. 
 
 
 
 
 
 
 
 
 Baseline Week 4 Week 12 p – value 
for trend  
TEG Indices     
R (min) 5.01 (1.38) 8.96 (1.45) 7.95 (1.79) 0.008 
K (min) 1.41 (0.36) 1.96 (0.86) 2.56 (1.03) 0.023 
Angle (degrees) 67.9 (6.9) 64.9 (10.7) 59.0 (11.8) 0.024 
MA (mm) 67.0 (5.5) 66.3 (8.7) 60.9 (13.8) 0.128 
LY60 (%) 4.0 (3.2 – 6.5) 2.7 (1.3 – 4.0) 1.2 (0.3 – 4.2) 0.649 
     
Turbidimetric & 
Fibrinolysis Indices 
    
Lag time (min) 6.3 (1.6) 8.5 (1.2) 8.2 (0.9) <0.001 
RCF (units/sec) 29.7 (8.5) 17.4 (7.5) 17.1 (6.4) <0.001 
MOD (units) 0.34 (0.08) 0.39 (0.10) 0.35 (0.06) 0.173 
RCD (units/sec) 36.2 (9.4) 50.3 (12.2) 50.2 (16.0) 0.001 
T50 (min) 4.1 (0.8) 3.0 (0.5) 3.0 (0.5) <0.001 
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Table 5.4.5: Fibrin clot at week 12 (Warfarin vs Apixaban) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean (standard deviation) or median (interquartile range). P values analysed by t-test 
or the Kruskall-Wallis test. 
*No statistical difference between both groups regarding comorbidities. 
 
 
 Warfarin (n = 10) Apixaban (n = 10) p - value 
Age  
(years) 
68.6 (17.1) 76.6 (11.5) 0.238 
Sex (male/female) 7/3 6/4 0.639 
SBP  
(mm Hg) 
123.3 (16.4) 129.6 (17.8) 0.422 
BMI  
(kg/m2) 
27.2 (8.0) 24.8 (4.0) 0.418 
Creatinine (µmol/L) 86.7 (15.7) 86.1 (29.3) 0.955 
Creatinine 
Clearance -
Cockcroft Gault 
(ml/min/1.73) 
70.3 (51.3 – 85.7) 65.2 (41.6 – 90.7) 0.403 
    
TEG Indices    
R (min) 8.66 (2.22) 7.16 (1.40) 0.094 
K (min) 2.05  
(1.48 – 3.18) 
1.80  
(1.60 – 2.70) 
0.652 
Angle (degrees) 56.0 (14.4) 62.3 (7.5) 0.250 
MA (mm) 57.9 (17.7) 60.6 (5.2) 0.659 
LY60 (%) 0.90 (0.23 – 3.5) 1.9 (0.55 – 5.1) 0.413 
    
Turbidimetric & 
Fibrinolysis Indices 
   
Lag time (min) 8.5 (1.0) 8.0 (0.7) 0.215 
RCF (units/sec) 14.2 (7.0) 20.2 (4.0) 0.036 
MOD (units) 0.376 (0.068) 0.326 (0.045) 0.072 
RCD (units/sec) 50.4 (10.8) 50.2 (14.3) 0.969 
T50 (min) 3.1 (0.4) 2.9 (0.5) 0.494 
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Section 6: Summary of findings and suggestions for future study 
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6.1 Summary of Findings 
The results of the fibrin clot structure in atrial fibrillation – effects of renal dysfunction can be 
summarised as follows: 
 An oral anticoagulant naïve individuals, AF is associated with formation of whole blood clot and 
fibrin clot which are of greater thrombotic potential and more resistant to lysis as compared to 
coronary artery disease (Section 5.1) 
 The adverse clot structure in AF can be shown to be modulated by exposure to warfarin or NOAC, 
with formation of fibrin clot and whole blood clot which are slower to form and more sensitive to 
fibrinolysis (Section 5.4). 
 Different oral anticoagulation agents result in formation of whole blood and fibrin clot with 
various structure changes. NOACs generally form clots which are more sensitive to fibrinolysis as 
compared to warfarin, however significant differences exist between individual NOAC used 
(Section 5.4). 
 In concurrent chronic kidney disease and AF, despite adequate oral anticoagulation with warfarin, 
changes to fibrin clot structure are present. Clot structure associated with renal dysfunction, in 
the presence of warfarin, possess greater thrombotic potential whilst more sensitive to 
fibrinolysis (Section 5.2).  
 Clot structure as demonstrated by SEM was of greater fibrin density and thicker fibres in those 
with worst renal dysfunction as compared to those with mildest CKD (Section 5.2). 
 Besides worsening creatinine clearance, structural changes to fibrin clots are shown to be 
independently associated with increased all-cause mortality over 2-year follow-up period (Section 
5.2). 
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 Relating to microparticles, worsening renal function was also shown to be associated with 
increased endothelial dysfunction as demonstrated by increased endothelial microparticle levels. 
However, other markers of prothrombotic state and cellular activations were demonstrated not 
to be significantly different across various degree of renal dysfunction (Section 5.3). 
 The current study is novel for two main reasons: 
o One: This study is first to demonstrate changes in fibrin clot structure as an independent 
predictor of all-cause mortality in patients with concurrent AF and CKD. Thus, with longer 
follow-up, adverse features in fibrin clot structure can potentially be a new prognostic 
marker. 
o Second: This study is also the first study to demonstrate favourable changes in fibrin clot 
for patients using NOACs as compared to VKA – thus future interventional study, fibrin 
clot structure has the potential to guide choice of anticoagulant use. 
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6.2 Suggestions for future study  
Based on the above findings, several future studies can be suggested: 
Firstly, to establish differences in whole blood clot structure and strength (assessed by TEG) as a result of 
each NOAC agent used, larger number of patients studied receiving dabigatran and apixaban can be 
recruited. The difference in fibrin clot structure as revealed by turbidimetric and fibrinolysis assay can 
also be visually confirmed by SEM of representative fibrin clots formed from NOAC users. 
Secondly, the difference between NOAC and VKA pre- and post-exposure is at most modest. Hence, to 
clarify and establish the changes to fibrin clot structure and strength relating to NOAC or VKA, larger 
longitudinal study involving more patients in both groups will be needed. 
Thirdly, due to the shorter half-life of NOAC (as short as 12 hours) as compared to VKA, alteration to 
changes to fibrin clot structure may be apparent within 36 – 72 hours of exposure. Thus to test this 
hypothesis, a short-term study, with frequent blood and plasma sampling every 12-24 hours will be able 
to demonstrate changes to haemostatic indices over time. 
Fourthly, with the increasing number of patients receiving NOAC, potential changes to clot structure in 
worsening degree of CKD amongst NOAC users will need to be assessed. 
Fifth, if NOAC proves to provide more favourable in fibrin clot structure as compared to VKA amongst 
patients with worsened CKD class, an interventional study can be done, randomising oral anticoagulant 
naïve individuals to NOAC or VKA. This allow for hard end-point such as ischaemic stroke and 
thromboembolism, mortality, haemorrhagic complications to be documented.  
Sixth in relation to CKD patients with AF undergoing haemodialysis, the use of apixaban has been 
approved in the United States by the FDA. Thus a comparison of fibrin clot structure in haemodialysis 
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patients receiving VKA or NOAC will be useful to better understand potential the effect of choice of renal 
replacement therapy and oral anticoagulant on haemostatic indices.     
Finally, for the 200 patients(anticoagulated with warfarin) who have been recruited with concurrent AF 
and CKD, long-term follow-up can be done to further investigate the impact of fibrin clot structure to risk 
of long-term mortality, strokes and major adverse cardiac events. 
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6.3 Conclusion   
Patients with AF and CKD experience an excessive risk of ischaemic stroke and thromboembolism. This 
thrombotic risk is not mitigated by the use of oral anticoagulation, but conferred in increased 
haemorrhagic sequelae. Meanwhile, patients with coronary disease and end-stage renal disease have 
been shown to possess changes to fibrin clot structure and characteristics.  
Therefore in the present MD thesis, fibrin clot structure and characteristics were studied in a variety of 
AF patients, by means of thromboelastography, turbidimetric and fibrinolysis assay, together with 
Scanning Electron Microscopy. In conjunction detection of markers for endothelial and platelet 
turnovers, and microparticles were also made. 
Therefore, based on the results above, it can be concluded that AF resulted in adverse clot structure 
which can increased thrombotic risk. And the clinical use of oral anticoagulant may aid risk mitigation 
due to favourable changes in resultant clot structure. However, for patients with the worst renal 
function and AF, the coexistence of both conditions and use of oral anticoagulation resulted in clot 
structures which are pro-thrombotic, but also more sensitive to fibrinolysis. Thus, this might potentially 
explain the paradox of increased thromboembolic and haemorrhagic risk in this cohort. 
To improve our understanding on the impact of structural changes to fibrin and whole blood clot and 
resultant morbidity and mortality benefit relating to renal failure and NOACs, further studies will be 
warranted.  
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X Appendices – (B) Patient Information Sheet 
 
 
 
 
 
 
 
PARTICIPANT INFORMATION SHEET 
 
1. Study title:     CLOT STRUCTURE IN ATRIAL FIBRILLATION 
 
2. Invitation paragraph 
You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is anything that 
is not clear or if you would like more information.  Take time to decide whether or not you wish to 
take part. 
Thank you for reading this.  
 
3. What is the purpose of the study? 
To find out the extent to which there is variation in clot formation in people with atrial fibrillation 
(AF) compared to people with cardiovascular disease (such as having had a heart attack or stroke, or 
have problems with the arteries of their legs)  
 
4. Why have I been chosen? 
You have been chosen because you have AF and/or cardiovascular disease 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect your professional relationship with the researcher 
or the Trust. 
 
  
Sandwell & West Birmingham Hospitals 
NHS Trust 
 
 
 
 
 
 176 
  
6. What will happen to me if I take part? 
After having signed the consent form, all we ask in a sample of your blood. In some people (and this 
might be you) we will ask for a second sample in about a month’s time, and a third in about three 
month’s time.  This is summarised in a diagram on the last page. 
You will also be given a copy of this information sheet and the signed informed consent form. 
Carefully retain these documents.  
 
7. What do I have to do? 
There is no restriction to your work pattern or any suggestion to change this. Continue to take all 
your medications and attend hospital and your GP exactly as you have been doing.  
 
8. What is the procedure that is being assessed? 
We want to find out if the ability of your blood to form a good firm clot depends on factors such as 
how well your kidneys work, and according to what drugs you are taking.  
 
9. What are the effects of participating in the study?  
None really: all we ask is a blood sample, but in some we will ask for three samples.  
 
10. What are the possible disadvantages and risks of taking part? 
Only that of a bruise in your arm as a result of the blood sample being taken. 
 
11. What are the possible benefits of taking part? 
None.  However, it is possible we may find out you have some problems you are unaware of (such as 
diabetes), and if so we will inform you and your GP. 
 
12. What if new information becomes available? 
Sometimes during the course of a research project, new information may become available about 
blood clotting. If this happens, the researcher will tell you about it and discuss with you whether you 
want to continue in the study.   
 
13. What happens when the research study stops? 
You will continue life just like before the study began, taking the same tablets and having the same 
hospital and GP appointments. You will continue to be cared for by your Doctors as if nothing had 
happened. 
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14. What if something goes wrong? 
If you are harmed due to someone’s negligent comment, then you may have grounds for a legal 
action but you may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms should be available to you. 
However there are no special compensation arrangements if you are harmed by simply participating 
in this research project.  
 
15. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you which leaves the hospital/surgery will have your name and 
address removed so that you cannot be recognised from it. 
 
16. What will happen to the results of the research study? 
The result of the study will be presented to our hospital colleagues and may be presented at 
scientific conferences, and published in peer reviewed scientific journals. However, no individual 
participant will be identified in any of the reports. 
 
17. Who is organising and funding the research? 
The project has been organised by a group of Doctors at Sandwell and West Birmingham NHS Trust. 
It is being funded by Departmental funds. There is no drug company involvement.  
 
18. Who has reviewed the study? 
This study has been reviewed by a committee of people independent from your doctor (the Local 
Research Ethic Committee), whose primary concerns are the safety, rights and welfare of patients in 
this study.  This committee has reviewed and approved all written material about this study 
including this information sheet and consent form. 
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19. Contact for Further Information 
If you would like more information about the research you could contact:  
 
 Dr Jocelyn Bell (The Head of our Department of Research and Development) on  
 
 
 Dr Andrew Blann (The principle investigator) on . His E-mail address is 
 
 
 Professor GYH Lip (Our Head of Department) on  
 
 The Hospital Patient Advice and Liaison Service on 0121 507 5836. Their E-mail address is 
pals@swbh.nhs.uk.  You also have the right to complain – and if you wish to then this is the 
unit your should contact 
 
 
Thank you for taking part in our study….. 
 
 
 
 
 
 
 179 
  
Participant Flow Chart 
This chart shows what will happen to you if you decide to take part 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. We approach 
you to see if you 
want to participate 
3. If you are able to take part, you will both sign three copies of the consent 
form: one for you, one for your hospital notes, and one for us. 
2. We give you a copy of the Patient Information 
Sheet and the Consent form to read 
4. The researcher will collect some details from 
you and takes a sample of blood 
5. For some people, we arrange for 
a second blood sample in about a 
month’s time 
5. For most people, your participation 
is complete 
6. We will arrange for a third and 
final blood sample in about three 
month’s time, after which your 
participation is complete. 
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X Appendices – (C ) Patient Consent Form    
  
 
 
Gregory YH Lip MD FRCP FACC Professor of Cardiovascular Medicine University of Birmingham Centre 
Paulus Kirchhof MD FRCP Professor of Cardiovascular Medicine for Cardiovascular Sciences 
Andrew D Blann PhD FRCPath Senior Lecturer in Medicine City Hospital, Birmingham 
Russell C Davis MD MRCP Senior Clinical Lecturer in Medicine B18 7QH, United Kingdom 
Deirdre Lane MSc PhD Lecturer in Medicine Departmental Secretary Ms S Cartwright 
Ronnie Haynes RGN MICR CMS Departmental Manager/Trials Co-ordinator Tel  Fax +  
   Direct Line to Dr Blann 
   Tel/fax   
Patient ID for this study: 
 
CONSENT FORM 
 
 
Title of Project: Clot Structure in Atrial Fibrillation  
Name of Researcher: Dr Yee Cheng Lau & Dr Andrew Blann 
Please initial all boxes 
 
1. I confirm that I have read and understand the information sheet dated 29
th 
August 2013 (version 1 for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
 
3. I agree to my GP being informed of my participation in the study. 
 
 
 
4. I agree to take part in the above study. 
 
 
5. I understand that to enable the study to be properly monitored and 
regulated, sections of my medical notes relevant to my taking part in this 
research and data collected during the study may be looked at by 
members of the research team, the NHS Trust where I will take part in the 
study, and regulatory agencies. 
I give permission for these individuals to have access to my records. 
 
 
 
Name of Participant Date Signature 
 
Name of Person Date Signature taking consent. 
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X Appendices – Consent Form (Healthy Control) 
 
